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The discovery of heparin in 1916 resulted in a huge impact on the practice of 
medicine. Heparin has played a major role in alleviating thrombotic disorders and has 
also exhibited effects on almost every major system in the human body. Over the past 
few decades, more and more heparin-protein interactions have come to light. It is 
implicated to modulate several important processes such as cell growth and 
differentiation, inflammatory response, viral infection mechanism etc. More interesting is 
the observation that these interactions are considerably specific with regard to 
oligosaccharide sequences which have specific spatially oriented  sulfate groups 
modulating the responses. However, due to the complex nature of these interactions and 
lack of effective computational capabilities, predicting these interactions is challenging. 
ix 
An alternative approach to modulating heparin-protein interactions would be to 
screen a library of molecules having a diverse distribution of the negative charges and 
screen them against various proteins of interest to obtain valuable information about the 
binding/selectivity requirements. This approach would not only yield molecules with 
potential clinical viability, but may also yield molecules that help decipher native 
mechanisms regulating proteins, which is called chemical biology in today‟s terms. Since 
the difficulties associated with carbohydrate synthesis are well known, well characterized 
highly sulfated oligosaccharide library screening is considered nearly impossible. Thus, 
the main aim of this project was to develop an effective method for the synthesis of a 
library of variably sulfated, non-carbohydrate molecules. The library would contain 
varying in the number of sulfate groups, offer positional variants of the sulfate groups 
and provide molecules of varying length so as to afford structural diversity necessary to 
mimic the heparin sequences.  
Previous attempts in our laboratory to synthesize such a library encountered two 
major problems: 1) dimerization of polyphenols due to difficult protection / deprotection 
strategies and 2) ineffective purification of highly water soluble sulfated molecules. To 
overcome the problem of protection-deprotection, “click” chemistry has been used in this 
work for dimerization of polyphenols without any protective groups. To overcome the 
second problem, a non-aqueous method of purification of highly sulfated molecules was 
developed, which is the first such report. 
x 
As a proof of concept, a small library of 14 sulfated monomers and dimers and 8 
non-sulfated dimers was generated. The protocol for dimerization of free polyphenolic 
molecules in  has been established to use “click” chemistry for coupling the monomers 
without the need to protect the free hydroxyl groups. Thus by circumventing the 
inefficient protection-deprotection protocol, there is a tremendous improvement in yields, 
ease of purification and characterization and greater productivity allowing the synthesis 
of more number of molecules in a relatively shorter span of time. By masking the charge 
of the sulfate using an appropriate counter-ion and owing to the inherent lipophilicity of 
the aromatic scaffold, these highly charged molecules could be purified using normal 
phase silica gel chromatography. This method reduced the purification time from 
previous over 48 hours with the aqueous method to approximately 15 minutes. Further, 
this purification protocol may be possibly automated so as to truly generate a large library 
of variably sulfated non-carbohydrate molecules for the first time. 
  Screening this library of 22 sulfated and unsulfated molecules against three 
enzymes of the coagulation cascade – factors IIa, Xa and XIa – has provided a wealth of 
information with regard to engineering specificity for recognition of these enzymes. The 
screening led to the identification of CS3 which inhibited factor XIa with an IC 50 of ~ 5 
μM and other enzymes with an IC 50 of > 500 μM as a lead candidate with high 
selectivity. The success of this strategy bodes well for understanding the heparin-protein 
interactions at a molecular level. 
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Chapter 1 Introduction 
 
1.1 Discovery and development of heparin 
The year 1916 marked the discovery of heparin by a medical student Jay McLean. 
This historic event took place in Dr. William Howell‟s laboratory at Johns Hopkins 
University.
1
 Over the next few decades, a lot of work was done on this new entity. The 
components of heparin were identified to be uronic acid and glucosamine in 1928 and 
1935-1936 by Howell and Jorpes - Bergstrom respectively.
2
 However, it was not until 
1940, that evidence for presence of a high sulfation pattern in heparin was provided by 
Jorpes and Charles.
3
 In 1968, Perlin et al. finally confirmed that L-iduronic acid was the 
uronic acid in heparin.
4
 Thus,  it was concluded, that heparin is a highly sulfated 
polysaccharide consisting of repeating iduronic acid and glucosamine units linked in a 1-
4 manner (Figure 1). In spite of it being discovered almost 20 years ago, it was not until 
1935 that sufficiently purified heparin could be obtained for testing its efficacy against 
post-operative thrombosis and thrombo-embolic disease in human subjects.
5,6
 This 
preparation, credited to the effort of Charles and Scott in Toronto and Jorpes in 
Stockholm, however, occasionally led to fever, chills, joint pain and other short term side 
effects.
6
 With better purification techniques, better understanding of the coagulation 
cascade and development of fractionated heparin in the form of low molecular weight 
heparin (LMW) heparin has formed an important part of drug therapy worldwide.
7
 
2 
Figure 1 General structure of heparin (Figure adapted from Henry, B. L.; Desai, 
U. R. Recent developments in the direct inhibition of coagulation proteinases-inhibitors 
of the initiation phase. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 323-336). 
 
 
 
 
 
1.2 Heparin-protein interactions 
Heparin is well known for its interactions with the proteins of the blood 
coagulation cascade. However, heparin and its derivatives have been shown to interact 
with a number of other proteins as well. In the circulatory system, heparin binds to and 
activates the antithrombin mediated inhibition of factor Xa, factor XIa and thrombin 
which are essential protein in the coagulation cascade. The end result of this inhibition is 
delaying of the clotting process. Heparin is also well known to affect various growth 
factors such as fibroblast growth factor (FGF), vascular endothelial growth factor 
(VEGF), endothelial factor (EF) and it is thus implicated as an anti-cancer agent. Its role 
in inflammatory processes is attributed to its interactions with endotoxin, tissue necrosis 
factor-α (TNF-α), neutrophils, adhesion molecules expressed on endothelial and 
leukocyte cell surface etc. Finally, preventing viral binding and internalization by 
recognizing viral coat proteins, heparin exhibits anti-viral properties  (Figure 2). 
 
3 
Figure 2 Heparin-protein interactions. (Figure adapted from Capila, I.; Linhardt. 
R. J. Heparin-protein interactions. Angew. Chem. Int. Ed. 2002, 41, 390-412.) 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Regulation of proteases  
Heparin-antithrombin III is the first and most well studied heparin-protein 
interaction. The potency of heparin as an anticoagulant is mainly due to its ability to 
accelerate the antithrombin III mediated inhibition of thrombin and  factor Xa. Serine 
protease inhibitors (SERPIN) form inactive complexes with serine proteases, which are 
then cleared from the body. More than 40 proteins belong to the serpin family. 
Antithrombin (AT) is one such protein.
8
 The mechanism by which this antithrombin 
mediated inhibition of serine protease occurs is called the serpin mouse trap mechanism. 
The reactive center loop (RCL) of antithrombin contains P1-P1‟ residues which bind to 
4 
the target serine protease. The P1-P1‟ bond is scissile and as soon as the Michaelis-
Menten complex (E:AT) is formed, this bond is cleaved. This results in the formation of 
the acyl-enzyme intermediate (E-AT), whose rearrangement leads to subsequent 
disruption of the catalytic triad of the enzyme (E*-AT*). Mutational changes in AT may 
lead to competition from a parallel pathway known as the substrate pathway. This leads 
to hydrolysis of the acyl-enzyme intermediate (E-AT), thus releasing the active enzyme 
(E) and the cleaved inhibitor (ATc) (Figure 3). In the presence of heparin, there is a 10
2
-
10
6
 fold increase in the rate of inhibition of fIIa, fXa, and fXIa.
9,10
 
The pentasaccharide sequence of heparin containing 5 residues DEFGH interacts 
with AT (Figure 4). Depending on the length of sequence binding, AT can inhibit the 
proteases by two mechanisms. Once the pentasaccharide is recognized by the AT, it leads 
to a change in conformation of the partially inserted RCL, followed by its accelerated 
cleavage.
9,11,12
 The second mechanism is the bridging mechanism, where binding of the 
AT to UFH is followed by non-specific binding of thrombin along the polysaccharide 
chain. The Michaelis-Menten complex (E: AT) is then formed by the diffusion of 
thrombin along the chain  (Figure 5).
 13
 
 
 
5 
Figure 3 A representation of the AT inhibition mechanism for serine proteases 
(Figure is adapted from Desai, U. R. New antithrombin based anticoagulants. Med. Res. 
Rev. 2004, 24, 151-181). 
 
 
 
 
 
 
 
 
Figure 4 The pentasaccharide binding sequence 
 
 
 
6 
Figure 5 The mechanisms of antithrombin inhibition of proteases in the 
presence of heparin (Figure adapted from Desai, U. R. New antithrombin based 
anticoagulants. Med. Res. Rev. 2004, 24, 151-181). 
 
 
 
 
 
 
7 
1.2.2 Regulation of cell growth factors 
Growth factors or fibroblast growth factors (FGF‟s) are a group of 23 proteins 
that are implicated in a variety of physiological processes such as cell proliferation, 
differentiation, morphogenesis and angiogenesis.
14
 Since the first evidence of inhibition 
of vascular smooth muscle cell growth by heparin in 1977, followed by the advent of 
heparin-agarose columns to purify growth factors in 1984, heparin and heparan sulfate‟s 
(HS) roles in cell growth and regulation are now well established facts.
15,16
 Heparin and 
cell surface HS play a dual role in stabilizing the binding of FGF to the fibroblast growth 
factor receptor (FGFR) and also promoting dimerization and subsequent of the FGFRs.
17
 
Besides, the affinity of vascular endothelial growth factor (VEGF) and epidermal growth 
factor (EGF) are also enhanced by HS and heparin.
18,19
 In addition, heparin and HS have 
the ability to directly affect receptor signaling and in turn modulate cell growth, 
independently without the involvement of protein ligands such as growth factors by direct 
interaction with „heparin receptors.20 Considering the close modulation of cell signaling 
and growth, their involvement in cancer is fairly intuitive and their role in tumorigenisis, 
angiogenesis and metastasis is well documented.
21,22
 
1.2.3 Regulation of inflammatory processes 
The existence of a subtle relationship between thrombosis and inflammatory 
diseases both in the vascular and cardiovascular systems.
23
 A well known representation 
of this phenomenon is the attainment of a hypercoagulable state due to generation of 
tissue factor (TF). This generation of tissue factor is the final outcomes of the various 
downstream pro-inflammatory responses due to exposure to interleukins or E. coli 
8 
endotoxin. We can thus conclude that coagulation and inflammation may be regulated by 
common molecules. The anti-inflammatory actions of heparin and HS are well 
documented.
24, 25
 This anti-inflammatory effect has been attributed to a number of 
interactions including but not limiting to endotoxin, tissue necrosis factor-α (TNF-α), 
neutrophils, adhesion molecules expressed on endothelial and leukocyte cell surface 
etc.
26-28
 Clinically, heparin has displayed the potential to be therapeutic in managing 
ulcerative colitis and Chron‟s disease.29,30 Surprisingly, during the course of these studies, 
no hemorrhagic complications were observed. It is thus hypothesized that heparin‟s anti-
inflammatory effect may be distinct from its anticoagulant effect. 
1.2.4 Role in viral infection mechanism 
The most important step in the pathogenesis of a virus is the initial attachment of 
the virus to the target cell surface.
2
 This initial binding of the viral envelope to specific 
receptors on the cell surface are followed by the internalization of the viron by fusion of 
the viral envelope with the cell membrane. Since HS are found on most cell surfaces, 
their role in viral binding and entry is not surprising.
31
 The importance of heparin and HS 
is further emphasized by the reduced binding of viruses to cells both in the absence of 
cell surface HS and in the presence of heparanases (enzymes cleaving HS).
32
 Thus, in the 
presence of soluble heparin or HS, viral infections are reduced as they bind to the virus 
and prevent it from binding and internalizing into the cell. This fact has been exploited to 
inhibit a number of viruses. Heparin shows anti-HIV activity by binding to the V3 loop 
which contains the viral surface glycoprotein gp120. It does not prohibit the virus from 
binding to the CD4 cells, but does not allow membrane fusion to take place.
33
 It has been 
9 
well demonstrated that viral entry of herpes simplex virus (HSV) both 1 and 2, along with 
other viruses of the herpes family such as human cytpmegalovirus (CMV), human herpes 
virus (HMV) and varicella zoster virus (VZV) require HS for the initial binding to host 
cell surface.
34
 Thus, molecules similar to heparin and HS hold potential anti-viral activity 
by preventing viral entry into the cell. This has been previously demonstrated in our 
laboratory where a sulfated lignins, which could possibly be mimics of HS, displayed 
viral inhibition.
35
 
1.3 Predicting heparin-protein interactions 
As more and more heparin binding proteins (HBP) were discovered, the value of 
understanding these highly specific interactions was highlighted. The idea was that if the 
proteins which interact with heparin could be predicted, based on these specific 
interactions, it would be easier to exploit heparin, in terms of synthetic mimics for its use 
therapeutically. A summary of the various heparin-binding proteins is presented in Table 
1.
2 
HBP Physiological Role Oligosaccharide 
size 
Kd Function of 
heparin 
AT III Coagulation cascade 5-mer 20 nM Enhances 
activity 
FGF-1 Cell proliferation, 
differentiation, 
angiogenesis etc. 
 
4-mer to 6-mer - Activates signal 
transduction 
IL-8 Pro-inflammatory 
cytokine 
 
18-mer to 20-mer 6 μM Promotes  
HIV-1 
gp120 
Viral entry into cell 10-mer 0.3 
μM 
Inhibits 
HSV  Viral entry and fusion Oligosaccharide 20 μM Inhibits 
10 
Cardin and Weintraub first investigated and tried to establish the general 
requirements for such heparin-protein interactions in 1989.
36
 Their study comprised of a 
comparative correlation between the heparin binding domains of four proteins, viz. 
apolipoprotein B, apolipoprotein E, vitronectin and platelet factor 4. They concluded that, 
besides having high sequence homology, these proteins displayed common motifs. They 
hypothesized that heparin binding proteins should display the following two motifs. The 
first motif, XBBXBX („B‟ stands for basic and „X‟ for hydropathic amino acid residues) 
should be present in the β-strand conformation while the second motif XBBBXXBX 
should be folded in an α-helix. For the von Willebrand factor, another heparin binding 
protein, a third motif, XBBBXXBBBXXBBX was proposed by Sobel and coworkers.
37
 
These motifs were thought to play the role of probes to identify and possibly give 
information about the important binding requirements of heparin to various proteins. But, 
with discovery of more and more heparin binding proteins, these hypothesis could not be 
applied to all these proteins. The fundamental drawback in this method was that it 
concentrated on the sequence proximity of the basic residues. In reality, however, the 
spatial orientation is more important as the protein folding may bring residues which are 
far away in terms of sequence, closer together. Conversely, the heparin chain should also 
have specific sequences and orientations to recognize and bind to specific proteins. 
Heparin and HS both have sulfo and carboxyl groups displayed at regular intervals and 
the defined orientations of these charged groups bestows it with this high level of 
specificity and affinity. There are numerous examples as evidence for this spatial 
specificity. The 3-O-sulfo group of the pentasaccharide unit of heparin is most essential 
11 
for its high affinity for antithrombin.
38
 Specificity within the same family of proteins has 
also been observed. 6-O-sulfo groups are not directly required for binding of FGF-2 to 
heparin but they are extremely important for FGF-1.
39
 Thus, considering the importance 
of heparin-protein interactions, there lacks a suitable method to provide information 
about these interactions. 
1.4 The need for a library of small sulfated molecules 
Ionic interactions predominate the variety of ways in which heparin interacts with 
proteins. The spatially defined sulfo and carboxyl groups form ion pairs with specific 
positively charged basic amino acid residues of the protein. As we saw earlier, a number 
of methods to study these interactions have been tried and failed. But, it is extremely 
essential to get more information about theses interactions as it will prove to be extremely 
valuable in terms of designing better, more selectively therapeutics. Thus, if we have a 
library of molecules differing in number and spatial orientation of sulfate groups, it 
would provide us with a great deal of information about these interactions. As easy as it 
sounds, obtaining a „library‟ of compounds is not an easy task. The scaffold must be 
chosen such that it has minimum synthetic complications. The yields should be high, 
there should be ease of purification and characterization and most importantly, the cost 
should be low.  
1.5 Difficulties in synthesizing an oligosaccharide library 
The most intuitive thing to do in this case would be to try and obtain a library of 
diverse sulfated oligosaccharides. However, the synthesis of oligosaccharides fail in 
every single requirement for library generation mentioned in the above paragraph. Even 
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nature for that matter, which is known for its selectivity and precision, makes saccharides 
in an apparent haphazard manner using a wide variety of enzymes in competition to 
produce a wide variety of products.
41
 Also, the absence of any information carrier 
encoding for a specific saccharide structure makes it impossible to adapt techniques 
popular for protein synthesis for synthesizing these oligosaccharide libraries.
42
 
Additionally, saccharides are usually branched rather than linear. Two types of linkages, 
viz. α or β can be used to connect the monomers gives rise to a new stereogenic center 
with each coupling reaction. The presence of a large number of functional groups of 
similar reactivities (hydroxyl and amino) necessitate the development of highly selective 
protection and deprotection strategies.
43
 Furthermore, with every glycosidic linkage, the 
complexity of the protection-deprotection strategy increases. The complexity of such 
synthesis becomes evident by the fact that greater than 15 million possible 
tetrasaccharides can be synthesized from the nine monosaccharides found in humans. 
Enzymatic synthesis of oligosaccharides was highly revered as a solution to all these 
problems associated with oligosaccharides. Making extensive protection-deprotection 
redundant, enzymes provide stereo and regioselectivity. It is thus easier to control the 
anomeric configurations and all this under extremely mild reaction conditions. Yet, the 
prohibitive cost and scarce availability of these enzymes and substrates are a major 
roadblock in this approach.
44
 Low yields coupled with inability to accept unnatural sugars 
as substrates makes oligosaccharide libraries a unrealistic proposition.
45
  
Despite  these difficulties,  groups have attempted synthesis of oligosaccharide 
libraries. In general three approaches are very popular for this purpose. The first method 
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is „random glycosylation‟ which involves non-selective coupling of a fucosyl donor to 
create three sub-libraries of α-fucosylated disaccharides (Scheme 1). This method yields 
an equiproportionate mixture of all possible trisaccharides in a single step. This method is 
known for its simplicity as it does not involve any complex protecting group 
manipulations. But, screening and hit identification is an extremely complex process as 
the samples are mixtures of molecules with identical molecular weight.
51
 Another popular 
strategy is the „split and mix‟ strategy. Mixtures of trisaccharide libraries of α/β linkage at 
every glycosidic linkage can be prepared. The method involves glycosylation of a 
monomer to form dimers with two possible linkages, which is split and reacted with two 
monomers to further from two possible products each (Scheme 2). In this way a mixture 
of 16 trisaccharides can be obtained.
52
 The third strategy is a „two-directional‟ 
glycosylation strategy using solid support. One of the The C6 hydroxyl group of a 
monosaccharide is immobilized on solid support and glycosylated with three different 
monomers to produce three different dimers. Another hydroxyl group is then deprotected, 
followed by a second set of glycosylation reactions with three monomers (Scheme 3). 
Thus, a mixture of 12 trisaccharides is obtained.
53
 Although a number of other methods 
have also been tried and published, these three are the most popular methods. As we can 
see from the results, a large number of molecules can be obtained through this method, 
however, the mixtures are extremely difficult to separate and characterize.
43
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Scheme 1 Random glycosylation 
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Scheme 2 Split and mix 
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Scheme 3 Two directional glycosylation using solid support 
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Furthermore, synthesis of a sulfated oligosaccharide library as heparin mimics 
adds another dimension of complexity to this already convoluted synthetic protocol. The 
hydroxyl groups that undergo sulfation in the end have to be selectively protected while 
those hydroxyl groups which will be further used to couple other monomers  have to 
remain free.
54
 This is extremely difficult to achieve considering the similar reactivities of 
these hydroxyl groups. Also, the formation of the oligosaccharide itself requires selective 
protection and deprotection strategies, thus the total number of different protecting 
groups used in a single monomer can be as high as five different agents.
55
 In addition, the 
amine group, further requires a different protecting group, usually an azide.
56
 
1.6 Alternate approach: Synthesis of a non-carbohydrate sulfated library 
Considering the above mentioned difficulties, it would seem like a good idea to 
try and synthesize diverse polysulfated compounds on an aromatic backbone. The wide 
range of reactions, the simple purification and characterization, the simplification of 
structure in terms of stereochemistry and the possibility of selecting a suitable scaffold 
having hydroxyl groups of different reactivities will probably makes this strategy 
synthetically more feasible. 
 However, even this synthesis is riddled with many problems. The first problem 
was that which scaffold would effectively mimic the polysaccharide scaffold. However, 
previous studies in our lab concluded that the flavonoid backbone was a good 
representative scaffold to work on.
46
  With the aim of obtaining structural diversity, it 
was very important to make flavonoid dimers or biflavonoids. This proved to be a major 
hurdle and obtaining the dimerized polyphenol with sufficient purity and yield was an 
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extremely difficult task. For the sulfation reaction, the difficulty in achieving a per 
sulfated molecule increases as the number of sulfate groups increase. However, the real 
difficulty lies in purification of these highly charged species. Aqueous chromatographic 
techniques such as size exclusion chromatography are used to purify these molecules and 
this results in great loss of time and yields. Thus, weighing both the options, the synthesis 
of a library based on the aromatic scaffold, in spite of having its share of difficulties 
seems plausible.  
1.7 The sulfation reaction 
Sulfation is a single step reaction, however the change in the physico-chemical 
properties of molecules after sulfation is extremely drastic making such chemistry 
extremely difficult. Besides the solubility issues, presence of inorganic salts is also a 
problem.
47
 Drastic reduction in the functional group transformations after sulfation, 
sensitivity to acidic conditions and high temperature and the necessity of using high 
quantities of starting material make this an extremely challenging task.
48
 However, given 
the importance of the sulfate group in biological as well as other applications several new 
methods have been developed to make this reaction more efficient. One of the initial 
instances of chemical sulfation was demonstrated in 1965 by use of sulfuric acid. 
However, as obvious as it seems, this method suffered from a number of drawbacks such 
as scaffold degradation, dehydration, non-selective sulfation.
48
 Subsequently 
dicyclohexylcarbodiimide-mediated sulfation and protection-deprotection strategies for 
sulfation where the sulfate is masked and introduced into the scaffold and eventually 
deprotected have been developed.
49,50
 However, the most effective method for sulfation, 
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developed by Raghuraman et al, has been a microwave assisted sulfation method using 
sulfurtrioxide complexed with base such as triethylamine. The hypothesis is that ionic 
conduction because of coupling of the microwaves with the sulfates may produce 
significant rate enhancements. This protocol can tolerate a wide range of functional 
groups such as amides, esters, aldehydes as well as alkenes. Besides the significant 
enhancement in yields (~70-95%) and short reaction duration (30 mins) makes this 
perfect for library synthesis.
47
 
1.7 Specific aims 
In order to synthesize a library of small sulfated molecules, the following synthetic 
difficulties have to be overcome. 
1. Choosing a scaffold similar to the flavonoids, however offering greater synthetic 
ease.  
2. Dimerization of molecules with high yields and easy purification 
3. Developing alternate means to purify sulfated molecules with enhanced yields. 
To overcome the synthetic difficulty associated with the flavonoid scaffold, the 
quinazolinone scaffold was selected. These two scaffolds share identical geometry, 
however, the presence of the amide hydrogen in the quinazolinone makes manipulation 
of the scaffold easy for subsequent dimerization (Figure 6). 
 
 
 
 
20 
Figure 6. Comparison of the flavone and quinazolinone scaffold 
 
 
 
 
 
Previously a number of strategies have been tried to dimerize the molecules. 
However, all these techniques required deprotection after dimerization to yield the 
polyphenol. This proved to be an extremely difficult step as the result was a complex 
mixture of partially deprotected molecules which was impossible to purify. The next 
logical step was to devise a way to dimerize the monomers without having to protect 
them, thus in turn removing the need for deprotection. The answer lied in one of the most 
popular reactions of recent times. Click chemistry consists of a copper catalyzed reaction 
where an azide containing monomer and an alkyne containing monomer are coupled by 
the formation of a triazole. The beauty of this reaction is that it can be carried out in the 
presence of free hydroxyl groups under mild conditions in good yields. Thus the 
problematic deprotection step is bypassed. Thus, the second aim is to establish a protocol 
for click based dimerization of the quinazolinone monomers and subsequently, optimize 
the reaction conditions to afford maximum yield. 
The next problem is associated with the purification of sulfated molecules. 
Traditionally since these are water soluble, aqueous chromatographic methods such as 
size exclusion chromatography have been used to purify these molecules. This led to a 
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substantial loss in yields. Also, since the fractions collected are so dilute, it is essential to 
start with large quantities to ensure detection and subsequent collection. This created a 
high synthetic burden. Due to the highly charged nature of these molecules, non-aqueous 
purification techniques are never considered. However, if we closely study the structure 
of these scaffolds, there is actually a higher percentage of lipophilic groups. Thus, the 
charge can be masked effectively, non-aqueous purification may be possible for these 
molecules. So the third aim will be to try using non-aquous purification techniques for 
the sulfated molecules and try and eventually try and achieve this using flash 
chromatography in order to save time, maximize yields and afford small sample size. 
The last and final aim will be to screen this library for direct inhibition of 
thrombin, factor Xa, factor XIa and indirect inhibition of factor Xa via antithrombin. First 
an initial screening using 500 μM concentration of the synthesized compounds will be 
performed and residual enzyme activity will be calculated. If any of the molecules show a 
100% reduction in enzyme activity at this concentration, then the IC50 will be calculated 
for that molecule. Subsequently for any promising results, Michaelis-Menten kinetics 
experiment will be performed in order to get more information about the type of 
inhibition and binding site. Finally, the results for all the enzymes will be compared and 
correlated to obtain valuable information about the binding requirements, selectivity 
requirements etc. 
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Chapter 2 Synthesis and Biological Evaluation of Sulfated Quinazolinone 
Monomers, Dimers and Poly-Phenolic Dimers 
 
 
2.1 Synthesis of the core quinazolinone scaffold 
The quinazolinone core structure was formed by a condensation reaction between 
anthranilamide and suitably substituted benzaldehyde. Depending on the substitution on 
the benzaldehyde, different monomers viz. 1L, 1M, 1N, 1O, 1P, 1Q and 1R were formed 
respectively. The products were formed in 45 - 65 % yields which decreased with 
increasing number of free hydroxyl groups. Standard water-ethyl acetate work up led to 
significant precipitation which drastically reduced the yield. With an aim to prevent this 
loss during work up two strategies were tried. First, we tried to reduce the volume of the 
reaction mixture to 5 ml and directly subjected it to flash chromatography without any 
work up. The result was inefficient separation and no improvement in yields. Next was a 
„hot‟ work up strategy . The reaction was monitored through TLC and once the reaction 
was complete, the temperature of the oil bath was reduced to 65° C. Water and ethyl 
acetate were added to this hot solution and stirred for 10 minutes. This hot solution was 
then transferred to a separating funnel, shaken vigorously and then separated 
immediately. The water layer was further given two more washing with hot ethyl acetate 
to ensure complete extraction of product. This procedure prevented precipitation and 
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 NaHSO3, DMA 
increased the overall yield to 60%. Another problem encountered was in the separation of 
unreacted anthranilamide from the product as they both displayed similar Rf values. To 
counter this the substituted benzaldehyde was taken in slight excess (1.2 equivalents as 
compared to 1 equivalent of anthranilamide) to ensure consumption of all the 
anthranilamide. 
    
 
 
 
 
 
 
2.1.2 Protection of quinazolinone monomer 
When selecting the protecting group, four important qualities were considered, 
viz. stability of the protecting group during other reactions, ease of deprotection, easy 
purification and short reaction time. Initially, trimethyl silane (TMS) was used as it 
satisfies all the above conditions. However, in the subsequent reactions, TMS was not 
found to be stable to potassium carbonate. Thus, diphenyl t-butyl silyl (TBDPS) was 
tried, but it suffered from low yields. Acetyl was later found to be the most effective 
protecting group. It has a number of options for deprotection from extremely strong 
reagents like 3M hydrochloric acid, mild reagents like lithium hydroxide to extremely 
1 2A : 3-OH 
2B : 3,5-OH 
2C : 3-OCH3, 4-OH 
2D : 3-OH, 4-OCH3 
2E : 2-OCH3, 3-OH, 4-OCH3 
2F : 2-OH, 4-OH 
2G : 2,4,6-OH 
 
1L : 3-OH 
1M : 3,5-OH 
1N : 3-OCH3, 4-OH 
1O : 3-OH, 4-OCH3 
1P : 3-OCH3, 4-OH, 5-OCH3 
1Q : 2-OH, 4-OH 
1R : 2,4,6-OH 
 
+ 
 
24 
selective agents like pyrrolidine. Reaction times are longer and yields relatively poorer as 
compared to TMS but better than TBDPS. As, the two most important condition were 
satisfied, acetyl was the protecting group of choice. 
 
 
 
 
 
2.1.3 Synthesis of propargylated quinazolinone monomer 
This is a simple SN2 type of reaction. The proton attached to „N’ is fairly acidic as 
the charge is resonance stabilized by the carbonyl group. Thus, it can be readily 
abstracted using a base. This then acts as the nucleophile. In this case potassium 
carbonate was used as base. Dimethyl formamide (DMF), a polar aprotic solvent is used  
to prevent solvation of the nucleophile which could prevent it from displacing the leaving 
group, i.e. the bromide. 
 
 
 
 
 
 
 
K2CO3, 
R.T. 
1L : 3-OH 
1M : 3,5-OH 
1N : 3-OCH3, 4-OH 
2L : 3-OAc 
2M : 3,5-OAc 
2N : 3-OCH3, 4-OAc 
 
 
2L : 3-OAc 
2M : 3,5-OAc 
2N : 3-OCH3, 4-OAc 
 
 
3L : 3-OAc 
3M : 3,5-OAc 
3N : 3-OCH3, 4-OAc 
 
 
Pyridine, Ac2O 
R.T. 
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2.1.4 Deacetylation of propargylated quinazolinone monomer 
Four different conditions were tried for this step. The results are summarized in 
the Table 2 below. Note that deacetylation was observed in all four cases. 
 
Reagent Observed Result 
3M HCl / Acetonitrile Displacement of side chain 
K2CO3 / Methanol Displacement of side chain 
Pyrrolidine (neat) No displacement of side chain but low yield 
Lithium hydroxide / THF Complete deacetylation & no side chain 
displacement 
 
First 3M HCl was used but significant deprotection was observed as side-
products. Alkaline conditions such as potassium carbonate in methanol also yielded the 
same result. This phenomenon is thought to occur due to resonance stabilization of the 
propargyl cation which makes it a good leaving group. 
 
 
 
It was then hypothesized that using mild reagents might prevent this from 
occurring. Thus, lithium hydroxide in tetrahydrofuran (THF) was tried. As expected, the 
side-chain remained intact along with successful deacetylation. The only problem was 
that as the number of hydroxyl groups increased, the reaction time proved to be very 
long, 10 – 15 hours. Pyrrolidine which is used for selective deprotection of phenolic 
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acetyl groups was hence attempted. The reaction in neat pyrrolidine takes 1-2 minutes as 
reported.
57
 However, the extraction in 3M HCl and ethyl acetate was not efficient and led 
to a huge loss in yield. Thus, we utilized lithium hydroxide in THF was used for  
preparative purposes. 
 
 
 
 
 
2.1.5 Synthesis of quinazolinone with alkyl chloro side-chain 
Similar to the propargylation reaction described in 2.3, this is a true SN2 type of 
reaction. The base used for abstraction of proton was potassium carbonate and solvent 
used was dimethyl formamide (DMF).  
 
 
 
 
 
2.1.6 Conversion of chloro to azide 
Two different parameters had to be explored in order to optimize this reaction - 
solvent and reaction temperature. The results of solvent manipulation are summarized in 
the Table 3 below 
LiOH, THF 
R.T. 
3L : 3-OAc 
3M : 3,5-OAc 
3N : 3-OCH3, 4-OAc 
 
 
4L : 3-OH 
4M : 3,5-OH 
4N : 3-OCH3, 4-OH 
 
 
5L : 3-OAc 
5M : 3,5-OAc 
5N : 3-OCH3, 4-OAc 
 
 
2L : 3-OAc 
2M : 3,5-OAc 
2N : 3-OCH3, 4-OAc 
 
 
R.T. 
K2CO3, 
R.T. 
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Solvent Outcome 
Ethanol No conversion along with deprotection 
DMF Complete conversion along with partial deprotection 
 
When ethanol was used as solvent, the chloride could not be displaced, however, 
the acetyl protecting groups were lost. Using DMF as an aprotic polar solvent resulted in 
the formation of the azide, which was confirmed by its characteristic IR peak at 2100  
cm
-1
. But TLC and NMR indicated partial deprotection of the acetyl groups. Thus, to 
overcome this phenomenon, the effect of temperature on deacetylation in presence of 
azide was studied. The results are summarized in the Table 4 below. Note that the yields 
are rough estimates based on TLC results. 
Temperature Outcome 
100° C Partial deprotection of acetyl group (60%) 
90° C Partial deprotection of acetyl group (60%) 
80° C Partial deprotection of acetyl group (50%) 
70° C Partial deprotection of acetyl group (20%) 
60° C No deprotection of acetyl group (0%) 
 
When the reaction was carried out at 60° C, no deprotection of the acetyl group 
was observed. Also, since the next reaction has to be deprotection of the acetyl group, it 
was logical to exploit higher temperature for azide formation as well as acetyl 
deprotection in one step, thus improving synthetic efficiency. We tried to optimize the 
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reaction so as to achieve this, however, we were never able to achieve complete 
deacetylation. It is assumed that the excess azide is the nucleophile which leads to the 
deprotection of the acetyl. The equivalents of the azide, which may account for the 
deacetylation, were thus increased to account for all the acetyl moieties, but complete 
deprotection was never observed. A complex mixture of fully deprotected, mono and 
diacetyl products was formed and was difficult to separate. Hence, both reactions were 
carried out separately. 
 
 
 
 
 
2.1.7 Partial and complete deprotection of quinazolinone azide 
This was fairly simple to achieve as compared to the deacetylation of the 
propargylated monomer. The partially deprotected monomer was obtained using lithium 
hydroxide and THF in 3 hours. 
 
 
 
 
 
 
5L : 3-OAc 
5M : 3,5-OAc 
5N : 3-OCH3, 4-OAc 
 
 
6L : 3-OAc 
6M : 3,5-OAc 
6N : 3-OCH3, 4-OAc 
 
 
LiOH, THF 
6M 7M 
NaN3, DMF 
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Complete deprotection of quinazolinone monomer was achieved using 3M HCl. 
 
 
 
 
  
2.1.8 Dimerization of quinazolinone monomers using click chemistry 
A number of techniques have been adopted for dimerization of molecules. 
However, in case of polyphenols, it has been previously observed that protection-
deprotection strategies prove to be a big hurdle in the formation of the final product.
58
 
The advantage of “Click” chemistry is that the final dimerization step can be performed 
in the presence of free hydroxyl groups. It is for this reason that the click chemistry 
approach was used for dimerization. 
Click chemistry is a copper catalyzed regioselective cycloaddition reaction 
forming the 1,4 – regiomer selectively. A number of different solvent combinations along 
with catalyst equivalents were screened in order to optimize the reaction. The results are 
summarized in Table 5 below: 
 
 
 
 
 
6L : 3-OAc 
6M : 3,5-OAc 
6N : 3-OCH3, 4-OAc 
 
 
7L : 3-OH 
8M : 3,5-OH 
7N : 3-OCH3, 4-OH 
 
 
3M HCl, 
ACCN 
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Solvent Combination Catalyst (CuSO4 : Na+ Ascorbate) Outcome 
t- BuOH / Water (20:80) 0.3 eq : 0.5eq No reaction 
t- BuOH / Water (30:70) 0.3 eq : 0.5eq No reaction 
t-BuOH / Water (50:50) 0.3 eq : 0.5eq No reaction 
DMF / Water (30:70) 0.3 eq : 0.5eq 30 % yield 
DMF / Water (50:50) 0.3 eq : 0.5eq 50 % yield 
DMF / Water (50:50) 0.1 eq : 0.5 eq 80 % yield 
 
Thus, copper catalyzed click reaction with 0.1 equivalents of copper sulfate and 
0.5 equivalents of sodium ascorbate was used to dimerize the polyphenolic monomers 
without any protection. This reaction was performed at room temperature to ensure the 
formation of the 1,4 regioisomer exclusively. 
 
 
 
 
 
 
 
 
 
 
+ 
 
6L : 3-OAc 
6M : 3,5-OAc 
7L : 3-OH 
7M : 3-OH, 5-OAc 
8M : 3,5-OH 
7N : 3-OCH3, 4-OH 
 
 
3L : 3-OAc 
4L : 3-OH 
4M : 3,5-OH 
4N : 3-OCH3, 4-OH 
 
 
 R / Rˈ 
C1 : 3-OAc / 3-OH 
C2 : 3-OH / 3-OAc 
C3 : 3-OH / 3-OH 
C4 : 3-OAc, 5-OH / 3-OH 
C5 : 3-OH, 5-OH / 3-OH 
C6 : 3-OH / 3-OH, 5-OH 
C7 : 3-OAc, 5-OAc / 3-OAc, 5-OAc 
C8 : 3-OAc, 5-OH / 3-OH, 5-OH 
C9 : 3-OH, 5-OH / 3-OH, 5-OH 
C10 : 3-OMe, 4-OH / 3-OMe, 4-OH 
 
CuSO4, 
Na
+
Ascorbate 
DMF / H2O 
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2.1.9 Sulfation of quinazolinone monomers and dimers 
Sulfation of the quinazolinone monomers and clicked dimers was achieved using 
microwave assisted sulfation reaction in the presence of a base, triethyl amine. For the 
first time, we report a  non-aqueous method of purification for these sulfated molecules. 
Contrary to popular belief, these highly charged molecules can be purified using normal 
phase silica gel chromatography. In this case we used flash chromatography. Since the 
sulfation reaction is done in the presence of base triethyl amine, the counter ion for the 
sulfate group after the reaction is triethyl amine. We hypothesize, it is because of the 
charge masking effect of this group that the separation using flash chromatography is 
possible. The solvent system used to make this separation possible was 
dichloromethane/methanol (0-20%). This method of purification was used for molecules 
with up to four sulfate groups with great ease and efficiency. The development of this 
method of purification has increased efficiency and yields in the process of making 
sulfated organic molecules. Thus synthesizing a large library of sulfated organic 
molecules is now less of a time consuming, labor intensive process. Once purified, the 
counter ion was exchanged with sodium to form the more stable sodium salt of the 
sulfated organic molecules. 
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1L : 3-OH 
1M : 3,5-OH 
1N : 3-OCH3, 4-OH 
1O : 3-OH, 4-OCH3 
1P : 2-OCH3, 3-OH, 4-OCH3 
1Q : 2-OH, 4-OH 
1R : 2,4,6-OH 
 
1S : 3-SO3
-
 
2S : 3,5- SO3
-
 
3S : 3-OCH3, 4- SO3
-
 
4S : 3- SO3
-
, 4-OCH3 
5S : 2-OCH3, 3-SO3
-
, 4-OCH3 
6S : 2,4- SO3
-
 
7S : 2,4,6- SO3
-
 
 
TEA, 
SO3Me3N 
50W, 90°C 
1 hour 
 R / Rˈ 
C2 : 3-OH / 3-OAc 
C3 : 3-OH / 3-OH 
C4 : 3-OAc, 5-OH / 3-OH 
C5 : 3-OH, 5-OH / 3-OH 
C7 : 3-OAc, 5-OH / 3-OH, 5-OH 
C8 : 3-OH, 5-OH / 3-OH, 5-OH 
C9 : 3-OMe, 4-OH / 3-OMe, 4-OH 
 
 R / Rˈ 
CS2 : 3-SO3
-
 / 3-OAc 
CS3 : 3-SO3
-
 / 3-SO3
-
 
CS4 : 3-OAc, 5-SO3
-
 / 3-SO3
-
 
CS5 : 3,5-SO3
-
 / 3-SO3
-
 
CS7 : 3-OAc, 5-SO3
-
 / 3,5-SO3
-
 
CS8 : 3,5-SO3
-
 / 3,5-SO3
-
 
CS9 : 3-OMe, 4-SO3
-
 / 3-OMe, 4-SO3
-
 
 
50W, 90°C 
1 hour 
TEA, 
SO3Me3N 
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2.2 Experimental section 
2.2.1 General methods 
Reagents/chemicals were purchased from Sigma-Aldrich (unless specified 
otherwise) and used as supplied. Analytical thin layer chromatography (TLC) was 
performed using UNIPLATE
TM
 silica gel GHLF 250 μm pre-coated plates (ANALTECH, 
Newark, DE) with a fluorescence indicator (254 nm). Flash chromatography was 
performed using Combi Flash
®
Rf flash chromatographer (TELEDYNE ISCO, Lincon, 
NE) with pre-packed RediSep
®
Rf silica gel columns. Microwave-assisted sulfation 
reactions were performed using CEM-Discover (Matthews, NC) synthesizer in sealed 
reaction vessels (7 ml). The reaction condition was set to ramp to 90°C at 30 W and was 
maintained by cooling with nitrogen at 45 psi. 
SP Sephadex-Na chromatography (cation exchange) was performed using flex 
columns (KIMBLE/KONTES, Vineland, NJ) of dimensions 75 × 1.5 cm. Cation 
exchange was performed using 30 fold excess of sodium ion equivalents. Samples were 
chromatographed at a controlled flow rate of 0.5 ml/min using water as eluent. Fractions 
of 5 ml each were collected and analyzed with a using thin layer chromatography (TLC) 
under conditions mentioned above. 
1
H NMR and 
13C NMR were recorded on Bruker Ultrashield™ Plus-400MHz 
spectrometer in CDCl3, DMSO-d6, CD3OD, CO(CD3)2 or D2O. All signals were reported 
in ppm with residual CDCl3, DMSO-d6, CD3OD, CO(CD3)2 or D2O signals at 7.26, 2.50, 
3.31, 2.05 and 4.79, respectively, as standards. The data is reported as chemical shifts 
(ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling 
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constant(s) (Hz) and integration. ESI mass spectra were recorded using Waters Acquity 
triple quadrupole mass spectrometer. Samples were dissolved in either methanol or 5% 
formic acid in water and infused at a rate of 20μl /min. Mass scans were obtained in the 
range of 200-1200 amu at a scan rate of 400 amu/sec. Ionization conditions were 
optimized for each compound to maximize ionization of the parent ion. The capillary 
voltage was varied between 3.0 to 5.0 kV, while cone voltage ranged from 28 to 35 V. 
For all experiments, the extractor voltage was set to 3.0 V, the Rf lens voltage to 0.1 V, 
source block temperature to 150° C and desolvation temperature to 250° C. 
Proteins – Human coagulation factors Xa, IIa (α-thrombin) and XIa were 
purchased from Haematologic Technologies (Essex Junction, VT). Stock solutions of 
proteins were prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM 
NaCl and 2.5 mM CaCl2 (thrombin and factor XIa) or 5 mM MES buffer, pH 7.4 (factor 
Xa). Chromogenic substrates Spectrozyme TH was purchased from American 
Diagnostica (Greenwich, CT) while substrate Chromogenix S-2765 (factor Xa) and 
Chromogenix S-2366 was from DiaPharma group, Inc (west Chester, Ohio). 
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Figure 7 General reaction scheme 
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2.2.2 General procedure for synthesis of quinazolinone core structure 
To a solution of anthranilamide 1 (1.0 equiv) in dimethyl acetamide were added 
the substituted benzaldehyde 2 (1.3 equiv) and sodium sulfate (1.0 equiv) in a single neck 
flask attached with a reflux condenser. The reaction mixture was vigorously stirred and 
heated to 145°C. After 24 hours, the hot mixture was extracted with water and ethyl 
acetate. The organic extract was dried (Na2SO4), concentrated in vacuo and purified using 
flash chromatography on silica gel (10-80% ethyl acetate in hexanes) to give 1A.  
2.2.3 General procedure for protection of quinazolinone core structure 
1A was then acetylated to protect the free hydroxyl group(s) by solubilizing in 
dichloromethane followed by addition of pyridine (2.0 equiv per hydroxyl group) and 
acetic anhydride (1.0 equiv per hydroxyl group). This was vigorously stirred at room 
temperature and after 10 hours extracted using acidified water and dichloromethane. The 
organic layer was dried (Na2SO4), concentrated in vacuo and purified using flash 
chromatography on silica gel (10-50% ethyl acetate in hexanes) to give 1B. 
2.2.4 General procedure for synthesis of the propargylated quinazolinone monomer 
To a solution of 1B in dimethyl formamide add potassium carbonate (1.5 equiv). 
Allow this reaction mixture to stir for 2 minutes and add propargyl bromide (1.5 equiv). 
After vigorous stirring for 12 hours at room temperature, extraction using water and ethyl 
acetate is carried out. The organic layer was dried (Na2SO4), concentrated in vacuo and 
purified using flash chromatography on silica gel (10-25% ethyl acetate in hexanes) to 
give 1C.  
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2.2.5 General procedure for deacetylation of the propargylated quinazolinone 
monomer 
1C was deacetylated by solubilizing in THF followed by addition of lithium 
hydroxide. This reaction mixture was vigorously stirred for 12 hours after which 1D was 
obtained by the extraction and purification method mentioned above. 
2.2.6 General procedure for addition of chloro alkyl side chain to quinazolinone 
scaffold 
To a solution of 1B in dimethyl formamide was added potassium carbonate (1.0 
equiv) and stirred for two minutes. This was followed by addition of 1-bromo-4-
chlorobutane and vigorous stirring for 12 hours. Extraction and purification by the above 
mentioned method yields 1E.  
2.2.7 General procedure for conversion of chloro to azide 
1E was then solubilized in dimethyl formamide in a flask attached to a reflux 
condenser and sodium azide (1.5 equiv) was added to it. The reaction mixture was 
vigorously stirred at 60°C to yield 1F after extraction and purification. The formation of 
1F was confirmed using IR as azides show characteristic IR peak at 2100 cm
-1
. 
2.2.8 General procedure for deacetylation of quinazolinone azide monomer 
1F was deacetylated by solubilizing in acetonitrile followed by addition of 3M 
HCl. This reaction mixture was refluxed at 80° C for 0.5 hours after which 1G was 
obtained by the extraction and purification method mentioned above. 
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 To obtain the partially deacetylated monomer 1H, it was solubilized in THF, 
followed by the addition of  LiOH. Vigorous stirring at room temperature for 6 hours 
afforded the product. 
2.2.9 General procedure for dimerization of quinazolinone monomers using click 
chemistry  
The monomers 1D (1.0 equiv) and 1G/1H (1.0 equiv) were solubilized in 
dimethylformamide. Freshly prepared solution of sodium ascorbate in water (0.5 equiv, 
0.1 mM) was added and allowed to stir. After 2 minutes, freshly prepared copper sulfate 
solution in water (0.1 equiv, 0.1 mM) was added. The reaction mixture was stirred 
vigorously for 12 hours at room temperature followed by extraction and purification to 
yield the dimerized quinazolinone 1I.  
2.2.10 General procedure for sulfation and sodium exchange for monomers and 
clicked dimers 
1I was solubilized in acetonitrile with tri-ethylamine (6 equiv per hydroxyl group) 
in a microwave reaction tube. Sulfur trioxide trimethyl amine (6 equiv per hydroxyl 
group) was added and the tube sealed. The reactions parameters for the microwave 
reactor were set according to the previously mentioned settings. After 45minutes the 
reaction mixture was transferred to a round bottom flask and volume reduced as much as 
possible under low pressure conditions at 25°C. The reaction mixture was then directly 
loaded on to a flash chromatography column and purified using dichloromethane and 
methanol solvent system (0-20%) to obtain the sulfated dimer 1J. This is further 
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chromatographed using the cation exchange column mentioned previously to obtain the 
sodium salt. 
2-(3-hydroxylphenyl)quinazolin-4(3H)-one (1L). Anthranilamide (2.5 g, 18.36 mmol) 
and 3-hydroxybenzaldehyde (2.91 g, 23.87 mmol) were dissolved in 25 ml DMA and 
reacted as per 2.2.2  to yield 2.39 g (67 % yield). Theoretical yield: 4.37 g. 
1
H NMR 
(400MHz, DMSO-d6) δ 8.16-8.14 (1H, m),  7.86-7.82 (1H, m), 7.73 (1H, d, J = 8Hz), 
7.60-7.58 (2H, m), 7.54-7.50 (1H, m), 7.34 (1H, t, J = 8), 6.99-6.97 (1H, m) (Figure 8). 
13
C NMR (100MHz, DMSO-d6) δ 162.16, 157.45, 152.32, 148.67, 134.58, 133.99, 
129.66, 127.41, 126.52, 125.80, 120.93, 118.48, 118.33, 114.51 (Figure 53). ESI (+ve) 
m/z calculated for C14H10N2O2 [(M+H)
+
] 239.24, found 239.14 (Figure 93).  
3-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (2L). 1L (1.5 g, 6.29 mmol) was 
dissolved in 20 ml dichloromethane followed by addition of pyridine (1.01 ml, 12.60 
mmol), acetic anhydride (1.2 ml, 12.60 mmol) and reacted as per 2.2.3 to yield 1.1 g (62 
% yield). Theoretical yield: 1.76 g. 
3-(4-oxo-3-(prop-2-yn-l-yl)-3,4-dihydroquinazolin-2-yl)phenyl acetate (3L). 2L (0.5 
g, 1.78 mmol), potassium carbonate (0.36 g, 2.67 mmol) and propargyl bromide 
(0.3184g, 2.67 mmol) were dissolved in 5 ml dimethylformamide and reacted as per 2.2.4 
to yield 0.4g (70 % yield). Theoretical yield: 0.57g. 
1
H NMR (400MHz, CDCl3) δ 8.41 
(1H, d, J = 7.88), 8.23 (1H, t, J = 1.88), 8.14-8.12 (1H, m), 7.92 (1H, d, J = 8.4), 7.79-
7.74 (1H, m), 7.49-7.43 (2H, m), 7.19-7.14 (1H, m), 5.26 (2H, d, J = 2.4), 2.49 (1H, t, J 
= 2.4), 2.28 (3H, s) (Figure 9). ESI (+ve) m/z calculated for C19H14N2O3 [(M+Na)
+
] 
341.33, found 341.16 (Figure 54).  
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2-(3-hydroxyphenyl)-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (4L). 3L (0.3 g, 0.94 
mmol), lithium hydroxide (0.079 g, 1.88 mmol) were dissolved in 4 ml THF and reacted 
as per 2.2.5 to yield 0.25 g (96 % yield). Theoretical yield: 0.26 g. 
1
H NMR (400MHz, 
MeOD) δ 8.18-8.16 (1H, m), 8.03-7.95 (3H, m), 7.89-7.87 (1H, m), 7.61-7.57 (1H, m), 
7.34 (1H, t, J = 7.92), 6.98-6.95 (1H, m),  5.36 (2H, d, J = 2.44), 3.04 (1H, t, J = 1.64) 
(Figure 10). 
13C NMR (100MHz, MeOD) δ 166.93, 161.29, 159.18, 158.75, 153.02, 
140.37, 136.89, 136.17, 135.24, 131.12, 130.46, 128.73, 128.47, 128.11, 127.98, 127.65, 
124.40, 122.32, 121.04, 118.88, 118.49, 116.34, 116.05, 115.92, 79.39, 79.16, 77.30, 
76.68, 74.29, 55.42 (Figure 55). 
3-(3-(4-chlorobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (5L). 1L (1.0 g, 
3.56 mmol) was solubilized in 10 ml DMF. To this potassium carbonate (0.98 g, 7.09 
mmol) along with 1-bromo-4-chlorobutane (0.62, 3.61 mmol) were added and reacted as 
per 2.2.6 to yield 1.1 g of 5L (83 % yield). Theoretical yield: 1.32 g. 
1
H NMR (400MHz, 
CDCl3) δ 8.39 (1H, d, J = 7.92), 8.22 (1H, t, J = 2.04), 8.09-8.07 (1H, m), 7.90 (1H, d, J 
= 8.36), 7.77-7.72 (1H, m), 7.47-7.41 (1H, m), 7.16-7.13 (1H, m), 4.68 (2H, t, J = 5.92), 
3.61 (2H, t, J = 6.36), 2.08-1.98 (4H, m). (Figure 11). 
13
C NMR (100MHz, CDCl3) δ 
169.45, 166.67, 158.98, 151.83, 151.00, 139.91, 133.58, 129.31, 128.07, 126.63, 125.86, 
123.65, 123.39, 121.49, 115.36, 66.11, 44.62, 29.59, 29.45, 26.22 (Figure 56). ESI (+ve) 
m/z calculated for C20H19ClN2O3 [(M+Na)
+
] 370.11, found 370.21 (Figure 94). 
3-(3-(4-azidobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (6L). 5L (0.5g, 
1.35 mmol) was solubilized in 6 ml DMF. To this sodium azide (0.14 g, 2.02 mmol) was 
added and reacted as per 2.2.7 to yield 0.4g of 6L (78 % yield). Theoretical yield: 0.509 
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g. 
1
H NMR (400MHz, CDCl3) δ 8.38 (1H, d, J = 7.88), 8.21 (1H, t, J = 1.96), 8.07-8.05 
(1H, m), 7.89 (1H, d, J = 8.36, 7.76-7.71 (1H, m), 7.46-7.41 (2H, m), 7.17-7.13 (1H, m), 
4.65 (2H, t, J = 6.24), 3.34 (2H, t, J = 6.76), 2.27 (3H, s), 2.00-1.93 (2H, m), 1.84-1.81 
(2H, m) (Figure 12). 
13
C NMR (100MHz, CDCl3) δ 169.49, 166.66, 158.96, 151.81, 
150.99, 139.90, 133.60, 129.33, 128.06, 126.65, 126.36, 125.86, 123.67, 123.39, 121.49, 
115.34, 66.22, 51.15, 26.10, 25.80, 21.21 (Figure 57). ESI (+ve) m/z calculated for 
C20H19ClN2O3 [(M+Na)
+
] 400.40 found 400.21 (Figure 95). 
3-(4-azidobutyl)-2-(3-hydroxyphenyl)quinazolin-4(3H)-one (7L). 6L (0.4g, 1.06 
mmol) was solubilized in 2 ml acetonitrile followed by addition of 2 ml 3M HCl and 
reacted as per 2.2.8 to yield 0.34 g (95 % yield). Theoretical yield: 0.355 g. 
1
H NMR 
(400MHz, (CD3)2CO) δ 8.55 (1H, s), 8.17-8.12 (3H, m), 7.94-7.92 (1H, m), 7.89-7.85 
(1H, m), 7.59-7.55 (1H, m), 7.37 (1H, t, J = 7.88), 7.05-7.02 (1H, m) 4.74 (2H, t, J = 
6.36), 3.49 (2H, t, J = 6.84), 2.09-2.04 (2H, m), 2.03-1.91 (2H, m) (Figure 13). 
13
C NMR 
(100MHz, CDCl3) δ 167.38, 160.37, 158.46, 152.67, 140.51, 134.55, 134.25, 130.50, 
130.22, 129.93, 128.69, 128.36, 127.46, 127.17, 126.37, 124.43, 124.18, 120.97, 120.71, 
120.39, 118.53, 118.08, 116.39, 116.09, 115.97, 115.79, 68.56, 67.17, 51.80, 26.75, 26.45 
(Figure 58). 
2-(3,5-dihydroxyphenyl)quinazolin-4(3H)-one (1M). Anthranilamide (2.0 g, 14.6 
mmol) and 3,5-dihydroxybenzaldehyde (2.43 g, 11.59 mmol) were dissolved in 20 ml 
DMA and reacted as per 2.2.2  to yield 1.43 g (45 % yield). Theoretical yield: 3.13 g. 
1
H 
NMR (400MHz, CD3OD) δ 8.24-8.21 (1H, m), 7.85-7.52 (1H, m), 7.50 (1H, d, J = 1.2), 
7.54-7.50 (1H, m), 6.95 (2H, d, J = 2.12), 6.51 (1H, t, J = 4.36) (Figure 14).
 13
C NMR 
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(100MHz, (CD3)2CO) δ 162.75, 159.76, 159.33, 153.14, 150.17, 136.09, 135.24, 128.60, 
127.23, 127.11, 122.41, 107.02 (Figure 59). ESI (+ve) m/z calculated for C14H10N2O3 
[(M+Na)
+
] 277.24 found 277.12 (Figure 96). 
5-(4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene diacetate (2M). 1M (1.0 g, 3.93 
mmol) was dissolved in 20 ml dichloromethane followed by addition of pyridine (1.27 
ml, 15.73 mmol), acetic anhydride (1.49 ml, 15.73 mmol) and reacted as per 2.2.3 to 
yield 1.2 g (90 % yield). Theoretical yield: 1.33 g. 
1
H NMR (400MHz, DMSO-d6) δ 
12.51 (1H, s), 8.17-8.15 (1H, m), 7.93 (2H, d, J = 2.08), 7.88-7.84 (1H, m), 7.76 (1H, d, 
J = 7.72), 7.58-7.54 (1H, m), 7.28 (1H, t, J = 2.08), 2.33 (6H, s) (Figure 15).
 
 
5-(4-oxo-3-(prop-2-yn-1-yl)-3,4-dihydroquinazolin-2-yl)-1,3-phenylene diacetate 
(3M). 2M (0.4 g, 1.17 mmol), potassium carbonate (0.326 g, 2.35 mmol) and propargyl 
bromide (0.28 g, 2.35 mmol) were dissolved in 5 ml dimethylformamide and reacted as 
per 2.2.4 to yield 0.33g (75 % yield). Theoretical yield: 0.44g. 
1
H NMR (400MHz, 
CDCl3) δ 8.14-8.11 (3H, m), 7.91-7.89 (1H, m), 7.79-7.76 (1H, m), 7.50-7.46 (1H, m), 
7.00 (1H, t, J = 2.16), 5.24 (2H, d, J = 2.44), 2.49 (1H, t, J = 2.44), 2.27 (6H, s) (Figure 
16).
 13
C NMR (100MHz, CDCl3) δ 169.00, 165.62, 157.77, 151.85, 151.18, 140.30, 
133.93, 128.11, 127.07, 123.52, 118.99, 117.55, 115.14, 115.04, 54.47, 21.15 (Figure 
60).
 
ESI (+ve) m/z calculated for C21H16N2O5 [(M+Na)
+
] 399.36 found 399.19 (Figure 
97). 
2-(3,5-dihydroxyphenyl)-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (4M). 3M (0.33 g, 
0.75 mmol), lithium hydroxide (0.25 g, 6.06 mmol) were dissolved in 4 ml THF and 
reacted as per 2.2.5 to yield 0.20 g (90 % yield). Theoretical yield: 0.22 g. 
1
H NMR 
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(400MHz, CH3OD) δ 8.19 (1H, d, J = 0.68), 7.96-7.87 (2H, m), 7.62-7.58 (1H, m), 7.52 
(2H, d, J = 2.28), 6.45 (1H, t, J = 2.28), 5.37 (2H, d, J = 0.24), 3.03 (1H, s) (Figure 17). 
13
C NMR (100MHz, CH3OD) δ 166.86, 161.34, 159.73, 152.99, 141.00, 135.22, 128.46, 
128.31, 124.40, 116.07, 106.09, 77.00, 54.79 (Figure 61). 
5-(3-(4-chlorobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene diacetate (5M) 
1M (0.42 g, 1.23 mmol) was solubilized in 5 ml DMF. To this potassium carbonate (0.34 
g, 2.47 mmol) along with 1-bromo-4-chlorobutane (0.31, 1.84 mmol) were added and 
reacted as per 2.2.6 to yield 0.45 g of 5M (84 % yield). Theoretical yield: 0.530 g. 
1
H 
NMR (400MHz, (CD3)2CO) δ 8.20 (2H, d, J = 2.16), 8.12-8.10 (1H, m), 7.93-7.86 (2H, 
m), 7.60-7.56 (1H, m), 7.16 (1H, t, J = 2.24), 4.70 (2H, t, J = 6.04), 3.77 (2H, t, J = 
6.32), 2.35 (6H, s), 2.12-2.10 (4H, m). (Figure 18). 
13
C NMR (100MHz, CDCl3) δ 
169.64, 167.59, 158.63, 152.45, 152.38, 141.21, 134.85, 128.74, 128.03, 124.26, 119.68, 
118.88, 116.10, 67.31, 45.70, 26.90, 21.15 (Figure 62). ESI (+ve) m/z calculated for 
C22H21ClN2O5 [(M+Na)
+
] 451.87, found 451.23 (Figure 98). 
5-(3-(4-azidobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene diacetate (6M). 
5M (0.31g, 0.74 mmol) was solubilized in 3 ml DMF. To this sodium azide (0.072 g, 
1.12 mmol) was added and reacted as per 2.2.7 to yield 0.31g of 6M (96 % yield). 
Theoretical yield: 0.32 g. 
1
H NMR (400MHz, CDCl3) δ 8.13 (2H, d, J = 2.24), 8.08-8.05 
(1H, m), 7.88 (1H, d, J = 8.2), 7.76-7.43 (1H, m), 7.47-7.43 (1H, m), 6.99 (1H, t, J = 
6.52), 4.64 (2H, t, J = 6.24), 3.32 (2H, t, J = 6.76), 2.26 (6H, s), 2.00-1.93 (2H, m), 1.84-
1.77 (2H, m) (Figure 19). 
13
C NMR (100MHz, CDCl3) δ 169.03, 166.70, 158.09, 151.80, 
151.69, 140.60, 133.68, 133.59, 128.10, 128.00, 126.85, 126.69, 123.41, 118.91, 117.41, 
44 
115.42, 66.31, 66.23, 51.14, 26.07, 25.79, 21.16 (Figure 63). ESI (+ve) m/z calculated 
for C22H21N5O5 [(M+Na)
+
] 458.43 found 458.29 (Figure 99). 
3-(3-(4-azidobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-5-hydroxyphenyl acetate 
(7M). 6M (0.15 g, 0.34 mmol) was solubilized in 2 ml THF followed by addition of 
LiOH (0.05 g, 0.034 mM) and reacted as per 2.2.8 to yield 0.1 g (74 % yield). Theoretical 
yield: 0.135 g. 
1
H NMR (400MHz, CDCl3) δ 8.12-8.09 (1H, m), 7.98-7.93 (2H, m), 7.85-
7.79 (2H, m), 7.54-7.50 (1H, m), 6.78 (1H, t, J = 2.24), 6.68 (1H, s), 4.68 (2H, t, J = 
6.28), 3.43 (2H, t, J = 6.76), 2.35 (3H, s), 2.07-2.00 (2H, m), 1.91-1.88 (2H, m) (Figure 
20). 
13
C NMR (100MHz, CDCl3) δ 169.75, 166.59, 158.95, 156.90, 151.70,151.48, 
140.42, 133.69, 127.73, 126.74, 123.38, 115.28, 113.80, 113.19, 111.56, 66.31, 51.13, 
26.04, 25.74, 21.21 (Figure 64). 
3-(4-azidobutyl)-2-(3,5-dihydroxyphenyl)quinazolin-4(3H)-one (8M). 6L (0.4g, 1.06 
mmol) was solubilized in 2 ml acetonitrile followed by addition of 2 ml 3M HCl and 
reacted as per 2.2.8 to yield 0.34 g (95 % yield). Theoretical yield: 0.355 g. 
1
H NMR 
(400MHz, (CD3)2CO) δ 8.55 (1H, s), 8.17-8.12 (3H, m), 7.94-7.92 (1H, m), 7.89-7.85 
(1H, m), 7.59-7.55 (1H, m), 7.37 (1H, t, J = 7.88), 7.05-7.02 (1H, m) 4.74 (2H, t, J = 
6.36), 3.49 (2H, t, J = 6.84), 2.09-2.04 (2H, m), 2.03-1.91 (2H, m)  (Figure 21). 
2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one (1N). Anthranilamide (2.0 g, 
14.68 mmol) and 3-hydroxy-4-methoxybenzaldehyde (2.68 g, 17.61 mmol) were 
dissolved in 25 ml DMA and reacted as per 2.2.2  to yield 2.83 g (84 % yield). 
Theoretical yield: 3.33 g. 
1
H NMR (400MHz, CH3OD) δ 8.24-8.21 (1H, m), 7.85-7.83 
(1H, m), 7.77-7.72 (2H, m), 7.60-7.57 (1H, m), 7.53-7.49 (1H, m), 6.96 (1H, d, J = 8.36), 
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4.00 (1H, s) (Figure 22). 
13
C NMR (100MHz, CH3OD) δ 162.38, 152.04, 149.93, 148.90, 
147.45, 134.47, 127.10, 125.90, 125.78, 123.33, 121.45, 120.52, 115.38, 111.31, 55.75 
(Figure 65). ESI (+ve) m/z calculated for C15H12N2O3 [(M+H)
+
] 269.27, found 269.19 
(Figure 100). 
2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (2N). 1N (2.0 g, 7.45 
mmol) was dissolved in 20 ml dichloromethane followed by addition of pyridine (1.17 g, 
14.90 mmol), acetic anhydride (1.52 ml, 14.90 mmol) and reacted as per 2.2.3 to yield 
1.5 g (54 % yield). Theoretical yield: 2.31 g. 
1
H NMR (400MHz, DMSO-d6) δ 12.60 
(1H, s), 8.18-8.16 (1H, m), 7.92 (1H, d, J = 1.88), 7.85-7.83 (2H, m), 7.76 (1H, d, J = 
7.92), 7.53 (1H, t, J = 7.2), 7.28 (1H, d, J = 8.32), 3.92 (3H, s), 2.31 (3H, s) (Figure 23).
 
13
C NMR (100MHz, DMSO-d6) δ 168.30, 162.21, 151.52, 150.81, 148.62, 141.71, 
134.61, 131.30, 127.50, 126.62, 125.82, 123.12, 120.92, 120.55, 112.01, 106.71, 56.07, 
20.38 (Figure 66). 
2-methoxy-4-(4-oxo-3-(prop-2-yn-1-yl)-3,4-dihydroquinazolin-2-yl)phenyl acetate 
(3N). 2N (0.18 g, 0.58 mmol), potassium carbonate (0.16 g, 1.16 mmol) and propargyl 
bromide (0.10 g, 0.87 mmol) were dissolved in 3 ml dimethylformamide and reacted as 
per 2.2.4 to yield 0.19g (95 % yield). Theoretical yield: 0.20g. 
1
H NMR (400MHz, 
CDCl3) δ 8.19 (1H, d, J = 1.8), 8.14-8.10 (2H, m), 7.91 (1H, d, J = 8.36), 7.77-7.73 (1H, 
m), 7.47-7.43 (1H, m), 7.09 (1H, d, J = 8.28), 5.23 (2H, d, J = 2.4), 3.92 (3H, s), 2.48 
(1H, t, J = 2.4), 2.27 (3H, s) (Figure 24).
 13
C NMR (100MHz, CDCl3) δ 168.84, 165.46, 
158.84, 152.01, 151.11, 141.94, 136.75, 133.80, 127.99, 126.71, 123.47, 121.39, 112.42, 
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78.22, 75.08, 56.04, 54.28, 20.74 (Figure 67).
 
ESI (+ve) m/z calculated for C20H16N2O4 
[(M+Na)
+
] 371.35 found 371.20 (Figure 101). 
2-(4-hydroxy-3-methoxyphenyl)-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (4N). 3N 
(0.12 g, 0.34 mmol), lithium hydroxide (0.043 g, 1.03 mmol) were dissolved in 3 ml THF 
and reacted as per 2.2.5 to yield 0.09 g (90 % yield). Theoretical yield: 0.10 g. 
1
H NMR 
(400MHz, CO(CD3)2) δ 8.26 (1H, d, J = 1.92), 8.21-8.15 (2H, m), 7.96-7.89 (2H, m), 
7.61-7.57 (1H, m), 6.99 (1H, d, J = 8.32), 5.42 (2H, d, J = 2.44), 3.99 (3H, s), 3.18 (1H, 
s) (Figure 25). 
13
C NMR (100MHz, CO(CD3)2) δ 166.15, 160.22, 153.05, 150.44, 
148.31, 134.81, 130.58, 128.55, 127.23, 124.05, 123.26, 115.73, 115.33, 112.46, 79.35, 
76.79, 56.60, 56.31, 55.08 (Figure 68). 
4-(3-(4-chlorobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methoxyphenyl acetate 
(5N). 1N (0.27 g, 0.87 mmol) was solubilized in 3 ml DMF. To this potassium carbonate 
(0.24 g, 1.74 mmol) along with 1-bromo-4-chlorobutane (0.22, 1.30 mmol) were added 
and reacted as per 2.2.6 to yield 0.31 g of 5M (91 % yield). Theoretical yield: 0.34 g. 
1
H 
NMR (400MHz, (CD3)2CO) δ 8.27 (1H, d, J = 0.18), 8.23-8.20 (1H, m), 8.15-8.13 (1H, 
m), 7.99 (1H, d, J = 8.36), 7.84-7.80 (1H, m), 7.53-7.49 (1H, m), 7.19 (1H, d, J = 8.28), 
4.72 (2H, t, J = 5.92), 4.02 (3H, s), 3.68 (2H, 6.32), 2.38 (3H, s), 2.15-2.11 (4H, m) 
(Figure 26). 
13
C NMR (100MHz, CDCl3) δ  168.84, 166.54, 159.11, 151.81, 151.11, 
141.89, 137.03, 133.54, 130.43, 127.95, 127.75, 126.48, 123.39, 122.64, 121.88, 121.34, 
115.19, 112.29, 111.65, 66.02, 65.88, 60.38, 56.06, 44.79, 44.66, 44.48, 29.25, 26.23, 
20.74, 20.64 (Figure 69). ESI (+ve) m/z calculated for C21H21ClN2O4 [(M+H)
+
] 401.86, 
found 401.23 (Figure 102). 
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4-(3-(4-azidobutyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methoxyphenyl acetate 
(6N). 5N (0.2g, 0.49 mmol) was solubilized in 3 ml DMF. To this sodium azide (0.048 g, 
0.99 mmol) was added and reacted as per 2.2.7 to yield 0.18g of 6N (90 % yield). 
Theoretical yield: 0.203 g. 
3-(4-azidobutyl)-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one (7N). 6N 
(0.15g, 0.36 mmol) was solubilized in 2 ml acetonitrile followed by addition of 1.5 ml 3 
M HCl and reacted as per 2.2.8 to yield 0.1 g (76 % yield). Theoretical yield: 0.13 g. 
1
H 
NMR (400MHz, CO(CD3)2) δ 8.24 (1H, d, J = 1.84), 8.20-8.17 (2H, m), 7.93-7.86 (2H, 
m), 7.57 (1H, t, J = 7.52), 6.38 (1H, d, J = 8.28), 4.81 (2H, t, J = 6.32), 3.53 (2H, t, J = 
6.8), 2.13-2.05 (4H, m) (Figure 27). 
13
C NMR (100MHz, CO(CD3)2) δ 167.28, 160.46, 
152.92, 150.33, 148.27, 134.51, 130.90, 128.49, 126.94, 1 24.21, 123.22, 115.70, 115.66, 
112.36, 67.09, 56.32, 51.81 (Figure 70). 
2-(3-hydroxy-4-methoxyphenyl)quinazolin-4(3H)-one (1O). Anthranilamide (1.0 g, 
7.34mmol) and 3-hydroxy-4-methoxybenzaldehyde (1.45 g, 9.53 mmol) were dissolved 
in 20 ml DMA and reacted as per 2.2.2  to yield 1.1 g (57 % yield). Theoretical yield: 
1.92 g 
2-(4-hydroxy-3,5-dimethoxyphenyl)quinazolin-4(3H)-one (1P). Anthranilamide (0.5 g, 
3.67 mmol) and 4-hydroxy-3,5-dimethoxybenzaldehyde (0.86 g, 4.40 mmol) were 
dissolved in 15 ml DMA and reacted as per 2.2.2  to yield 0.6 g (55 % yield). Theoretical 
yield: 1.09 g.  
2-(2,4-dihydroxyphenyl)quinazolin-4(3H)-one (1Q). Anthranilamide (0.5 g, 3.67 
mmol) and 4-hydroxy-3,5-dimethoxybenzaldehyde (0.67 g, 4.40 mmol) were dissolved in 
48 
15 ml DMA and reacted as per 2.2.2  to yield 0.62 g (66 % yield). Theoretical yield: 0.93 
g 
2-(2,4,6-trihydroxyphenyl)quinazolin-4(3H)-one (1R). Anthranilamide (0.5 g, 3.67 
mmol) and 2,4,6-trihydroxybenzaldehyde (0.74 g, 4.77 mmol) were dissolved in 15 ml 
DMA and reacted as per 2.2.2  to yield 0.07 g (7 % yield). Theoretical yield: 0.99 g. 
1
H 
NMR (400MHz, CDCl3) δ 9.50 (1H, s), 8.22 (1H, d, J = 1.08), 8.21-7.66 (2H, m), 7.43-
7.39 (1H, m), 6.10 (2H, s) (Figure 28).  
3-(3-(4-(4-((2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)methyl)-1H-1,2,3-triazol-
1-yl)butyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (C1). 6L (0.224 g, 
0.5935 mM) and 4L (0.164 g, 0.5935 mM) were solubilized in DMF followed by 
addition of sodium ascorbate (0.06, 0.2967 mM) and CuSO4 (0.044 mg, 0.1780 mM) and 
reacted as per 2.2.9 to yield 0.32 g (82 % yield). Theoretical yield: 0.38 g. 
1
H NMR 
(400MHz, CO(CD3)2) δ 8.40 (1H, d, J = 7.88), 8.29-8.13 (5H, m), 7.88-7.76 (4H, m), 
7.53-7.24 (6H, m), 7.06-7.04 (1H, m), 5.83 (2H, s), 4.60-4.55 (4H, m), 2.32 (3H, s), 2.19-
2.16 (2H, m), 1.95-1.91 (2H, m) (Figure 29). 
13
C NMR (100MHz, CO(CD3)2) δ 169.95, 
167.36, 166.81, 163.15, 160.11, 159.33, 158.65, 152.69, 152.40, 152.20, 143.76, 140.55, 
140.29, 134.66, 134.63, 130.34, 130.14, 128.65, 127.69, 127.50, 126.48, 125.18, 124.85, 
124.19, 124.16, 122.37, 120.67, 118.71, 116.18, 115.91, 115.78, 67.09, 61.00, 50.59, 
27.86, 26.55 (Figure 71). ESI (+ve) m/z calculated for C37H31N7O5  [(M+H)
+
] 654.69, 
found 654.44 (Figure 103). 
3-(3-((1-(4-(2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-triazol-4-
yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (C2). 7L (0.224 g, 0.5935 
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mM) and 3L (0.164 g, 0.5935 mM) were solubilized in DMF followed by addition of 
sodium ascorbate (0.06, 0.2967 mM) and CuSO4 (0.044 mg, 0.1780 mM) and reacted as 
per 2.2.9 to yield 0.28 g (80 % yield). Theoretical yield: 0.38 g. 
1
H NMR (400MHz, 
CO(CD3)2) δ 8.40 (1H, d, J = 7.88), 8.29-8.13 (5H, m), 7.88-7.76 (4H, m), 7.53-7.24 (6H, 
m), 7.06-7.04 (1H, m), 5.83 (2H, s), 4.60-4.55 (4H, m), 2.32 (3H, s), 2.19-2.16 (2H, m), 
1.95-1.91 (2H, m) (Figure 30).  
2-(3-hydroxyphenyl)-3-((1-4-(2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)butyl)-
1H-1,2,3-triazol-4-yl)methyl)quinazolin-4(3H)-one (3C). 7L (0.15 g, 0.4474 mM) and 
4L (0.14 g, 0.4474 mM) were solubilized in DMF followed by addition of sodium 
ascorbate (0.04, 0.2237 mM) and CuSO4 (0.033 mg, 0.1342 mM) and reacted as per 2.5.9 
to yield 0.2 g (74 % yield). Theoretical yield: 0.27 g. 
1
H NMR (400MHz, DMSO d-6) δ 
8.39 (1H, s), 8.13-8.02 (2H, m), 8.01-7.95 (2H, m), 7.94-7.91 (6H, m), 7.62-7.57 (2H, 
m), 7.36-7.31 (2H, m), 6.95-6.91 (2H, m), 5.83 (2H, s), 4.69 (2H, t, J = 4), 4.53 (2H, t, J 
= 8), 2.14-2.08 (2H, m), 1.91-1.88 (2H, m) (Figure 31). 
13
C NMR (100MHz, DMSO d-6) 
δ 166.06, 165.61, 158.96, 158.82, 157.57, 157.52, 151.24, 151.10, 142.13, 138.74, 
134.27, 134.10, 129.52, 129.45, 127.56, 127.52, 127.06, 126.95, 124.65, 123.21, 119.08, 
118.99, 117.92, 117.83, 114.75, 114.71, 114.52, 114.40, 65.97, 59.90, 49.18, 48.56, 
26.51, 25.30. (Figure 72). ESI (+ve) m/z calculated for C35H29N7O4  [(M+H)
+
] 612.65, 
found 612.49 (Figure 104). 
3-hydroxy-5-(3-(4-(4-((2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)methyl)-1H-
1,2,3-triazol-1-yl)butyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate (4C). 7M 
(0.12 mg, 0.3126 mM) and 4L (0.086 mg, 0.3126 mM) were solubilized in DMF 
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followed by addition of sodium ascorbate (0.031 mg, 0.1563 mM) and CuSO4 (0.023 mg, 
0.0937 mM) and reacted as per 2.2.9 to yield 0.16 g (76 % yield). Theoretical yield: 0.20 
g. 
1H NMR (400MHz, MeOD) δ 8.06 (1H, s), 7.92-7.90 (1H, m), 7.86-7.81 (3H, m), 7.73 
(2H, s), 7.69-7.63 (3H, m), 7.54-7.53 (1H, m), 7.35-7.31 (2H, m), 7.16 (1H, t, J = 7.84), 
7.11 (1H, s), 6.81-6.78 (1H, m), 6.54 (1H, t, J = 2.24), 5.66 (2H, s), 4.43-4.39 (4H, m), 
3.21-3.19 (2H, m), 2.16 (3H, s), 2.05-1.98 (2H, m), 1.79-1.72 (2H, m) (Figure 32). 
13
C 
NMR (100MHz, MeOD) δ 171.18, 167.84, 167.31, 161.11, 160.38, 159.58, 158.77, 
153.27, 152.92, 152.68, 144.47, 141.33, 140.37, 135.11, 134.98, 130.54, 128.45, 128.37, 
128.03, 127.98, 125.90, 124.47, 124.43, 120.91, 118.83, 116.28, 116.11, 113.95, 113.86, 
112.29, 67.37, 60.88, 30.68, 27.92, 26.80 (Figure 73). ESI (+ve) m/z calculated for 
C37H31N7O6  [(M+H)
+
] 670.69, found 670.45 (Figure 105). 
2-(3,5-dihydroxyphenyl)-3-(4-(4-((2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-
yl)methyl)-1H-1,2,3-triazol-1-yl)butyl)quinazolin-4(3H)-one (5C). 8M (89 mg, 0.25 
mM) and 4L (79 mg, 0.2533 mM) were solubilized in DMF followed by addition of 
sodium ascorbate (30 mg, 0.1519 mM) and CuSO4 (12.6 mg, 0.0506 mM) and reacted as 
per 2.2.9 to yield 0.12 g (72 % yield). Theoretical yield: 0.16 g. 
1
H NMR (400MHz, 
MeOD) δ 8.32 (2H, t, J = 1.72), 8.13 (1H, s), 7.98-7.70 (6H, m), 7.42-7.34 (4H, m), 6.88 
(2H, d, J = 8.72), 6.43 (1H. t, J = 2.28), 5.74 (2H, s), 4.51 (4H, t, J = 6.52), 2.16-2.09 
(2H, m), 1.88-1.83 (2H, m) (Figure 33). 
13C NMR (100MHz, MeOD) δ 167.63, 167.11, 
164.86, 161.49, 161.32, 159.68, 152.97, 152.64, 144.53, 141.20, 134.97, 134.83, 131.46, 
130.26, 128.22, 127.90, 127.74, 127.32, 125.80, 124.45, 124.38, 116.28, 108.25, 106.09, 
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67.27, 60.77, 36.96, 31.67 (Figure 74). ESI (+ve) m/z calculated for C35H27N7O5  
[(M+H)
+
] 628.65, found 628.46 (Figure 106). 
2-(3,5-dihydroxyphenyl)-3-((1-(4-(2-(3-hydroxyphenyl)-4-oxoquinazolin-3(4H)-
yl)butyl)-1H-1,2,3-triazol-4-yl)methyl)quinazolin-4(3H)-one (6C). 7M (0.08 mg, 
0.2394 mM) and 4M (0.07 mg, 0.2394 mM) were solubilized in DMF followed by 
addition of sodium ascorbate (0.023 g, 0.1197 mM) and CuSO4 (0.017 g, 0.0718 mM) 
and reacted as per 2.2.9 to yield 0.09 g (60 % yield). Theoretical yield: 0.15 g. 
1
H NMR 
(400MHz, MeOD) δ 8.14 (1H, s), 7.94-7.84 (4H, m), 7.79-7.69 (4H, m), 7.48 (2H, d, J = 
2.24), 7.39-7.34 (2H, m), 7.25 (1H, t, J = 8.16), 6.90-6.88 (1H, m), 6.45 (1H, t, J = 2.28), 
5.70 (2H, s), 4.49 (4H, t, J = 6.56), 2.13-2.08 (2H, m), 1.88-1.84 (2H, m) (Figure 34). 
13C NMR (100MHz, MeOD) δ 167.69, 167.10, 161.34, 161.02, 159.77, 158.62, 152.76, 
152.60, 144.41, 141.01, 140.50, 135.00, 134.86, 130.45, 128.25, 128.17, 127.86, 127.77, 
125.90, 124.39, 120.96, 118.71, 116.32, 116.06, 116.01, 108.20, 106.17, 67.30, 60.78, 
51.25, 27.94, 26.82 (Figure 75). ESI (+ve) m/z calculated for C35H29N7O5  [(M+H)
+
] 
628.65, found 628.42 (Figure 107). 
5-(3-((1-(4-(2-(3,5-diacetoxyphenyl)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-
triazol-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene diacetate (7C). 
6M (65 mg, 0.15 mM) and 4H (56.18 mg, 0.15 mM) were solubilized in DMF followed 
by addition of sodium ascorbate (14.77 mg, 0.0746 mM) and CuSO4 (11.15 mg, 0.0447 
mM) and reacted as per 2.2.9 to yield 0.01 g (8.3 % yield). Theoretical yield: 0.1211 g. 
1H NMR (400MHz, MeOD) δ 8.27 (1H, s), 8.17-8.11 (5H, m), 8.02-7.87 (6H, m), 7.56-
7.53 (2H, m), 7.08-7.04 (2H, m), 5.82 (2H, s), 4.60-4.50 (5H, m), 2.33 (12H, d, J = 8), 
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2.18-2.04 (2H, m), 1.87-1.84 (m, 2H) (Figure 35). ESI (+ve) m/z calculated for 
C43H37N7O10  [(M+Na)
+
] 834.79, found 834.54 (Figure 108). 
3-(3-(4-(4-((2-(3,5-dihydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)methyl)-1H-1,2,3-
triazol-1-yl)butyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-5-hydroxyphenyl acetate (8C). 
7M (40.3 mg, 0.10 mM) and 4H (30 mg, 0.1026 mM) were solubilized in DMF followed 
by addition of sodium ascorbate (12.18 mg, 0.0615 mM) and CuSO4 (5.12 mg, 0.0205 
mM) and reacted as per 2.2.9 to yield 0.04 g (57 % yield). Theoretical yield: 0.07 g. 
1
H 
NMR (400MHz, MeOD) δ 8.12 (1H, s), 7.96 (2H, t, J = 8.84), 7.78-7.70 (5H, m), 7.56 
(1H, t, J = 1.88), 7.40-7.39 (4H, m), 6.55 (1H, t, J = 2.2), 6.32 (1H, t, J = 2.24), 5.71 (2H, 
s), 4.73-4.44 (4H, m), 2.20 (3H, s), 2.09-2.05 (2H, m), 1.84-1.80 (2H, m) (Figure 36). 
13C NMR (100MHz, MeOD) δ 171.21, 167.97, 167.28, 161.21, 160.48, 159.81, 159.61, 
153.29, 152.94, 152.76, 144.48, 141.36, 141.03, 135.13, 135.04, 128.48, 128.37, 128.11, 
127.99, 125.99, 124.49, 116.35, 116.17, 113.95, 113.86, 112.29, 108.17, 106.15, 67.41, 
60.84, 27.93, 26.84, 21.01 (Figure 76). ESI (+ve) m/z calculated for C37H31N7O7  
[(M+H)
+
] 686.68, found 686.51 (Figure 109). 
2-(3,5-dihydroxyphenyl)-3-((1-(4-(2-(3,5-dihydroxyphenyl)-4-oxoquinazolin-
3(4H)yl)butyl)-1H-1,2,3-triazol-4-yl)methyl)quinazolin-4(3H)-one (9C). 8M (0.08 g, 
0.2326 mM) and 4M (0.068 g, 0.2326 mM) were solubilized in DMF followed by 
addition of sodium ascorbate (0.027 g, 0.1395 mM) and CuSO4 (0.029 mg, 0.1163 mM) 
and reacted as per 2.2.9 to yield 0.06 g (40 % yield). Theoretical yield: 0.14 g. 
1
H NMR 
(400MHz, MeOD) δ 8.19 (1H, s), 8.02-7.98 (3H, m), 7.82-7.78 (4H, m), 7.47-7.26 (7H, 
m), 6.43-6.41 (2H, m), 5.77 (2H, s), 4.56-4.54 (4H, m), 2.16 (2H, s), 1.90 (2H, s) (Figure 
53 
37). 
13C NMR (100MHz, MeOD) δ 167.81, 167.24, 164.87, 161.42, 161.07, 159.77, 
159.69, 152.70, 152.27, 144.45, 140.90, 140.85, 135.11, 135.04, 128.19, 127.98, 127.93, 
125.96, 124.48, 117.22, 116.12, 116.07, 108.23, 108.17, 106.18, 67.44, 60.83, 51.25, 
27.91, 26.82 (Figure 77). ESI (+ve) m/z calculated for C35H29N7O6  [(M+H)
+
] 644.65, 
found 644.43 (Figure 110). 
2-(4-hydroxy-3-methoxyphenyl)-3-((1-(4-(2-(4-hydroxy-3-methoxyphenyl)-4-
oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-triazol-4-yl)methyl)quinazolin-4(3H)-one 
(10C). 7N (0.10 g, 0.2938 mM) and 4N (0.09 g, 0.2938 mM) were solubilized in DMF 
followed by addition of sodium ascorbate (0.034 g, 0.1762 mM) and CuSO4 (0.036 g, 
0.1469 mM) and reacted as per 2.2.9 to yield 0.05 g (25 % yield). Theoretical yield: 
0.197 g. 
1H NMR (400MHz, MeOD) δ 8.24-8.20 (1H, m), 8.09-8.04 (4H, m), 7.88-7.72 
(5H, m), 7.53-7.44 (2H, m), 6.98-6.90 (2H, m), 5.81 (2H, s), 4.63-4.57 (2H, m), 4.14-
4.09 (2H, m), 3.97 (6H, s), 2.23-2.19 (2H, m), 1.98-1.92 (2H, m) (Figure 38). 
13
C NMR 
(100MHz, MeOD) δ 165.04, 164.63, 157.86, 157.63, 150.37, 150.31, 149.74, 149.40, 
142.95, 142.28, 142.16, 134.29, 134.18, 133.67, 133.45, 126.37, 126.16, 125.71, 125.56, 
124.38, 122.40, 121.59, 120.91, 113.39, 113.31, 111.94, 65.77, 55.67, 55.63, 50.09, 
42.42, 26.23, 25.01 (Figure 78).  
3-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (1S). 1L (0.05 g, 0.2098 mM), was 
solubilized in 3 ml acetonitrile followed by addition of triethylamine (0.18 ml, 1.2592 
mM) and SO3Me3N (0.175 g, 1.2592 mM) and allowed to react as per 2.2.10 to yield 0.05 
g (75 % yield). Theoretical yield: 0.066 g. 
1
H NMR (400MHz, D2O) δ 7.89-7.87 (1H, m), 
7.69-7.63 (3H, m), 7.56-7.52 (1H, m), 7.48-7.45 (2H, m), 7.36 (1H, t, J = 7.8) (Figure 
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39). 
13
C NMR (100MHz, D2O) δ 151.41, 135.56, 133.50, 130.56, 127.52, 125.74, 125.40, 
124.97, 120.78, 119.42 (Figure 79). ESI (-ve) m/z calculated for C14H9N2O5S
-
  [(M)
-
] 
317.30, found 317.17 (Figure 111). 
5-(4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene bis(sulfate) (2S). 1M (0.05 g, 
0.1966 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.32 ml, 2.3599 mM) and SO3Me3N (0.328 g, 2.3599 mM) and allowed to react as per 
2.2.10 to yield 0.06 g (74 % yield). Theoretical yield: 0.081 g. 
1
H NMR (400MHz, D2O) 
δ 8.13-8.11 (1H, m), 7.86-7.82 (1H, m), 7.72-7.68 (3H, m), 7.54 (1H, t, J = 8), 7.48 (1H, 
t, J = 2.16) (Figure 40). 
13
C NMR (100MHz, D2O) δ 152.17, 135.76, 134.72, 127.81, 
125.96, 118.56, 118.31 (Figure 80). ESI (-ve) m/z calculated for C14H8N2O9S2
-2
  
[(M+Na)
+
] 435.35, found 435.10 (Figure 112). 
2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (3S). 1N (0.05 g, 
0.1863 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.16 ml, 1.1182 mM) and SO3Me3N (0.15 g, 1.1182 mM) and allowed to react as per 
2.2.10 to yield 0.05 g (80 % yield). Theoretical yield: 0.064 g. 
1
H NMR (400MHz, D2O) 
δ 7.96 (1H, d, J = 8), 7.71 (1H, t, J = 7.76), 7.53 (1H, d, J = 8.2), 7.47-7.35 (4H, m), 3.90 
(3H, s) (Figure 41). 
13
C NMR (100MHz, D2O) δ 151.45, 142.88, 135.63, 130.40, 127.48, 
125.86, 122.82, 120.64, 119.49, 112.57, 56.27 (Figure 81). ESI (-ve) m/z calculated for 
C15H11N2O6S
-
  [(M)
-
] 347.32, found 347.16 (Figure 113). 
2-methoxy-5-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (4S). 1O (0.05 g, 
0.1863 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.16 ml, 1.1182 mM) and SO3Me3N (0.15 g, 1.1182 mM) and allowed to react as per 
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2.2.10 to yield 0.045 g (70 % yield). Theoretical yield: 0.064 g. 
1
H NMR (400MHz, D2O) 
δ 7.70-7.68 (1H, m), 7.60-7.54 (2H, m), 7.45-7.42 (1H, m), 7.34 (1H, d, J = 8.12), 7.24-
7.20 (1H, m), 6.95 (1H, d, J = 8.8), 3.78 (3H, s) (Figure 42). 
13
C NMR (100MHz, D2O) δ 
154.27, 139.79, 135.42, 127.07, 126.69, 125.60, 123.91, 121.70, 118.89, 113.17, 56.08 
(Figure 82). ESI (-ve) m/z calculated for C15H11N2O6S
-
  [(M)
-
] 347.32, found 347.16 
(Figure 114). 
2,6-dimethoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (5S). 1P (0.05 g, 
0.1676 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.14 ml, 1.0056 mM) and SO3Me3N (0.14 g, 1.0056 mM) and allowed to react as per 
2.2.10 to yield 0.035 g (55 % yield). Theoretical yield: 0.063 g. 
1
H NMR (400MHz, D2O) 
δ 7.90 (1H, d, J = 0.92), 7.65 (1H, t, J = 1.36), 7.63 (1H, d, J = 1.36), 7.36 (1H, t, J = 
7.24), 7.04 (2H, s), 3.86 (6H, s) (Figure 43). 
13
C NMR (100MHz, D2O) δ 154.24, 135.52, 
132.18, 129.95, 127.47, 125.74, 119.42, 105.18, 56.44 (Figure 83). ESI (-ve) m/z 
calculated for C16H13N2O7S
-
  [(M)
-
] 377.35, found 377.17 (Figure 115). 
4-(4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene bis(sulfate) (6S). 1Q (0.05 g, 
0.1966 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.32 ml, 2.3599 mM) and SO3Me3N (0.328 g, 2.3599 mM) and allowed to react as per 
2.2.10 to yield 0.06 g (74 % yield). Theoretical yield: 0.081 g. 
1
H NMR (400MHz, D2O) 
δ 7.94 (1H, s), 7.79-7.72 (2H, m), 7.52-7.38 (4H, m) (Figure 44). 13C NMR (100MHz, 
D2O) δ 154.18, 149.45, 135.61, 131.95, 127.73, 126.00, 125.85, 119.45, 116.27, 55.61, 
42.50, 38.73 (Figure 84). ESI (-ve) m/z calculated for C14H8N2O9S2
-2
  [(M+Na)
+
] 435.35, 
found 435.16 (Figure 116). 
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2-(4-oxo-3,4-dihydroquinazolin-2-yl)benzene-1,3,5-triyl tris(sulfate) (7S). 1R (0.05 g, 
0.1850 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.46 ml, 3.3303 mM) and SO3Me3N (0.463 g, 3.3303 mM) and allowed to react as per 
2.2.10 to yield 0.06 g (53 % yield). Theoretical yield: 0.093 g. 
1
H NMR (400MHz, D2O) 
δ  (Figure 45). 13C NMR (100MHz, D2O) δ 163.47, 162.28, 155.63, 154.40, 143.92, 
135.33, 126.61, 125.27, 123.44, 118.05, 98.16, 55.58 (Figure 85). 
3-(3-(4-(4-((2-(3-acetoxyphenyl)-4-oxoquinazolin-3(4H)-yl)methyl)-1H-1,2,3-triazol-
1-yl)butyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (CS2). C2 (0.05 g, 0.0765 
mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine (0.04 ml, 
0.4592 mM) and SO3Me3N (0.063 g, 0.4592 mM) and allowed to react as per 2.2.10 to 
yield 0.05 g (89 % yield). Theoretical yield: 0.056 g. 
1
H NMR (400MHz, D2O) δ 8.39-
8.37 (1H, m), 8.33 (1H, s), 8.26 (1H, t, J = 1.92), 8.20 (1H, t, J = 1.96), 8.16-8.15 (1H, 
m), 8.02 (2H, d, J = 8.16), 7.89-7.82 (4H, m), 7.55-7.50 (3H, m), 7.41-7.30 (2H, m), 
7.24-7.21 (1H, m), 5.76 (2H, s), 4.61 (2H, t, J = 6.4), 4.64 (2H, t, J = 6.96), 2.07-2.03 
(2H, m), 1.84 (2H, s) (Figure 46). 
13
C NMR (100MHz, D2O) δ 169.29, 166.11, 165.81, 
158.70, 157.85, 153.85, 151.10, 150.82, 142.04, 138.84, 138.36, 134.40, 134.11, 129.69, 
128.81, 127.58, 127.38, 126.98, 125.46, 124.80, 124.22, 123.27, 123.20, 123.16, 122.95, 
121.29, 120.44, 114.51, 114.50 (Figure 86). ESI (-ve) m/z calculated for C37H30N7O8S
-
  
[(M)
-
] 732.74, found 732.38 (Figure 117). 
3-(3-((1-(4-(2-(3-phenylsulfate)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-triazol-4-
yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (CS3). C3 (0.09 g, 0.1308 
mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine (0.2ml, 
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1.5706 mM) and SO3Me3N (0.2 g, 1.5706 mM) and allowed to react as per 2.2.10 to yield 
0.08 g (70 % yield). Theoretical yield: 0.113 g. 
1
H NMR (400MHz, D2O) δ 7.53-6.53 
(16H, m), 5.11 (2H, s), 4.24 (2H, s), 3.62 (2H, s), 1.65 (2H, s), 1.26 (2H, s) (Figure 47). 
13
C NMR (100MHz, D2O) δ 154.62, 151.52, 151.37, 151.02, 149.67, 149.38, 145.07, 
142.68, 142.42, 138.21, 138.08, 136.39, 134.55, 133.70, 133.54, 130.28, 129.57, 127.21, 
126.54, 126.31, 125.64, 125.31, 125.07, 124.33, 123.18, 122.26, 122.08, 121.17, 120.83, 
119.94, 118.94, 113.42, 113.32, 65.92, 59.25, 55.53, 50.04, 39.56, 26.28, 25.00 (Figure 
87). ESI (-ve) m/z calculated for C35H27N7O10S2
-2
  [(M+Na)] 792.76, found 792.36 
(Figure 118). 
3-(3-((1-(4-(2-(3-acetoxy-5-phenylsulfate)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-
triazol-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate (CS4). C4 (0.06 
g, 0.0895 mM), was solubilized in 3 ml acetonitrile followed by addition of triethylamine 
(0.15 ml, 1.0751 mM) and SO3Me3N (0.150 g, 1.0751 mM) and allowed to react as per 
2.2.10 to yield 0.05 g (64 % yield). Theoretical yield: 0.074 g. 
1
H NMR (400MHz, D2O) 
δ 7.97 (1H, s), 7.87 (1H, s), 7.58-7.53 (2H, m), 7.24-6.99 (9H, m), 6.74-6.59 (3H, m), 
5.25 (2H, s), 4.33 (2H, t, J = 5.96), 3.70-3.65 (2H, m), 2.23 (3H, s), 1.72 (2H, s), 1.32 
(2H, s) (Figure 48). 
13
C NMR (100MHz, D2O) δ 172.29, 165.30, 165.09, 157.94, 157.09, 
151.76, 151.51, 150.50, 149.65, 149.31, 142.83, 139.07, 138.07, 133.82, 129.67, 126.72, 
125.74, 125,64, 125.30, 123.59, 122.46, 122.17, 120.87, 118.43, 118.24, 116.86, 113.57, 
113.47, 65.96, 59.15, 55.49, 50.14, 26.23, 25.01, 20.54 (Figure 88). ESI (-ve) m/z 
calculated for C37H29N7O12S2
-2
  [(M+Na)] 850.80, found 850.39 (Figure 119). 
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5-(3-(4-(4-((2-(3-phenylsulfate)-4-oxoquinazolin-3(4H)-yl)methyl)-1H-1,2,3-triazol-1-
yl)butyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene bis(sulfate) (CS5). C5 
(0.05 g, 0.0792 mM), was solubilized in 3 ml acetonitrile followed by addition of 
triethylamine (0.2 ml, 1.4263 mM) and SO3Me3N (0.2 g, 1.4263 mM) and allowed to 
react as per 2.2.10 to yield 0.055 g (80 % yield). Theoretical yield: 0.068 g. 
1
H NMR 
(400MHz, D2O) δ 8.52-8.50 (2H, m), 8.33-8.31 (3H, m), 8.02-7.97 (2H, m), 7.83-7.77 
(4H, m), 7.48-7.44 (5H, m), 5.77 (2H, s), 4.62-4.57 (4H, m), 2.20-2.14 (2H, m), 1.96-
1.91 (2H, m) (Figure 49). 
13
C NMR (100MHz, D2O) δ 167.93, 167.39, 160.51, 159.86, 
156.45, 154.71, 152.91, 152.73, 144.29, 141.07, 135.32, 135.23, 135.12, 130.83, 128.62, 
128.35, 128.28, 128.02, 126.18, 124.58, 124.53, 122.06, 118.89, 118.09, 116.27, 115.90, 
67.63, 61.01, 28.13, 26.93 (Figure 89). ESI (-ve) m/z calculated for C35H26N7O14S3
-3
  
[(M-SO3
-
)] 786.82, found 786.33 (Figure 120). 
5-(3-((1-(4-(2-(3-acetoxy-5-phenylsulfate)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-
triazol-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene bis(sulfate) 
(CS7). C7 (0.01 g, 0.0178 mM), was solubilized in 3 ml acetonitrile followed by addition 
of triethylamine (0.04 ml, 0.3215 mM) and SO3Me3N (0.44 g, 0.3215 mM) and allowed 
to react as per 2.2.10 to yield 0.006 g (50 % yield). Theoretical yield: 0.012 g. 
1
H NMR 
(400MHz, MeOD) δ 8.62 (1H, s), 8.45 (2H, d, J = 2.16), 8.34 (1H, t, J = 1.52), 8.14-8.04 
(3H, m), 7.92-7.82 (4H, m), 7.57 (2H, m), 7.38 (1H, t, J = 2.16), 7.25 (1H, t, J = 2.16), 
5.84 (2H, s), 4.66-4.58 (4H, m), 2.33 (3H, s), 2.22-2.17 (2H, m), 1.95-1.91 (2H, m)  
(Figure 50). 
13C NMR (100MHz, MeOD) δ 171.02, 168.11, 167.48, 159.77, 159.72, 
154.78, 152.97, 152.70, 141.29, 140.82, 135.22, 135.11, 128.72, 128.57, 128.38, 128.30, 
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124.68, 124.54, 119.83, 119.11, 118.59, 118.28, 118.02, 116.42, 116.37, 67.66, 28.11, 
26.86, 21.01 (Figure 90). ESI (-ve) m/z calculated for C37H29N7O13S2
-2
  [(M-2SO3-1H+)] 
764.80, found 764.37 (Figure 121). 
5-(3-((1-(4-(2-(3,5-dihydroxyphenyl)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-1,2,3-
triazol-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-1,3-phenylene bis(sulfate) 
(CS8). C8 (0.01 g, 0.0162 mM), was solubilized in 3 ml acetonitrile followed by addition 
of triethylamine (0.05 ml, 0.3898 mM) and SO3Me3N (0.054 g, 0.3898 mM) and allowed 
to react as per 2.2.10 to yield 0.006 g (40 % yield). Theoretical yield: 0.015 g. 
1
H NMR 
(400MHz, MeOD) δ 8.61 (1H, s), 8.47 (2H, d, J = 2.2), 8.35 (2H, d, J = 2.2), 8.19-8.10 
(2H, m), 7.95-7.85 (2H, m), 7.57 (2H, t, J = 7.48), 7.44 (1H, t, J = 2.2), 7.37 (1H, t, J = 
2.2), 5.87 (2H, s), 4.72 (2H, t, J = 6.32), 4.61 (2H, t, J = 6.92), 2.25-2.21 (2H, m), 1.99-
1.93 (2H, m) (Figure 51). 
13C NMR (100MHz, MeOD) δ 168.12, 167.53, 160.10, 159.82, 
154.84, 154.64, 153.03, 152.85, 143.93, 141.06, 140.84, 135.28, 135.10, 128.77, 128.63, 
128.36, 128.32, 127.18, 124.60, 118.96, 118.54, 118.19, 118.00, 116.42, 116.40, 67.71, 
60.67, 28.24, 26.93, 24.99 (Figure 91). ESI (-ve) m/z calculated for C35H25N7O18S4
-4
  
[(M-3SO3-1H+)] 722.87, found 722.30 (Figure 122). 
4-(3-((1-(4-(2-(4-hydroxy-3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl)butyl)-1H-
1,2,3-triazol-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methoxyphenyl 
sulfate (CS9). (0.03 g, 0.0446 mM), was solubilized in 3 ml acetonitrile followed by 
addition of triethylamine (0.08 ml, 0.5359 mM) and SO3Me3N (0.074 g, 0.5359 mM) and 
allowed to react as per 2.2.10 to yield 0.02 g (54 % yield). Theoretical yield: 0.037 g. 
1
H 
NMR (400MHz, MeOD) δ 7.86 (1H, s), 7.38-7.07 (10H, m), 6.86-6.70 (3H, m), 5.06 
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(2H, s), 4.35 (2H, s), 3.62 (6H, d, J = 6.44), 1.73 (2H, s), 1.36 (2H, s) (Figure 52). 
13
C 
NMR (100MHz, MeOD) δ 165.04, 164.63, 157.86, 157.63, 150.37, 150.31, 149.74, 
149.40, 142.95, 142.28, 142.16, 134.29, 134.18, 133.67, 133.45, 126.16, 125.71, 125.56, 
124.38, 122.40, 121.59, 120.91, 113.39, 113.31, 111.94, 55.67, 55.63, 50.09, 42.42, 
26.23, 25.01 (Figure 92). ESI (-ve) m/z calculated for C35H25N7O18S4
-4
  [(M+Na)] 
852.81, found 852.40 (Figure 123). 
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Chapter 3 Results and Discussion 
 
 
3.1 Dimerization of quinazolinones using click chemistry 
A number of different approaches have been tried to dimerize molecules. Some of 
the most popular methods are: 1. Ulmann coupling of halogenated monomers, 2. metal-
catalyzed cross coupling, 3. phenol oxidative coupling and 4. nucleophilic substitution. 
Ulmann coupling is probably one of the oldest dimerization methods. It is a 
copper catalyzed coupling of aryl halides. However, high reaction temperatures (260-300 
°C) and poor yields (20-30%) (Scheme 4).
60
 Metal catalyzed cross coupling reactions is 
another way which has been used extensively. It consists of two main type of reactions, 
Stille coupling and Suzuki coupling. Stille reaction is a coupling reaction in which an 
organotin compound is coupled with an sp
2
 hybridized organohalide catalyzed by 
palladium (Scheme 5).
61
 The high cost of the palladium catalyst, the need for an 
extremely oxygen free environment and the high probability of side reactions are the 
major drawbacks associated with such chemistry.
62
 Suzuki is again a palladium catalyzed 
reaction between the aryl, vinyl boronic acid with aryl or vinyl halide (Scheme 6).
63
 This 
is an excellent option if the boronic acid derivative is commercially available as the point 
of contention is synthesis of the boronic acid derivative of the required starting material 
since it is problematic. Nucleophilic substitution is the simplest approach which can be 
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used for dimerization. In this case, dihaloalkanes, dihaloalkenes, dihalophenyls can be 
used as linkers in a SN2 type reaction (Scheme 7).
59
 Thus, in spite of a large number of 
options being available, none of the above reactions satisfy the requirements needed in a 
reaction for the purpose of synthesizing a library. 
Scheme 4 General scheme for Ulmann Coupling 
 
 
Scheme 5 General scheme for Stille Coupling 
 
 
Scheme 6 General scheme for Suzuki Coupling 
 
 
Scheme 7 General scheme for Nucleophilic Substitution 
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Despite the drawbacks of the above mentioned reactions, synthesizing a library of 
small organic molecules either by dimerization or any other method has been pursued and 
mastered in the last decade. From the years 2005 to 2009 alone, in excess of 2200 
libraries of small molecules each containing hundreds of molecules of varying scaffolds 
have been generated.
72-76
 Different approaches like solid-support chemistry, 
combinatorial chemistry, multicomponent reactions etc. have been used for achieving this 
feat.
15
 Production of small molecule libraries via high-throughput extraction, purification 
and characterization has also gained popularity in recent times.
77
 However, in this huge 
collection of small molecules, there in not a single library which contains molecules that 
can mimic heparin. In other words, creating a library of non-saccharide sulfated small 
molecules has never been attempted before. 
The production of such a library of small sulfated molecules is necessary as it 
would probably unravel important information about heparin-protein interactions. Thus, 
the first aim of this thesis project was thus, to try and establish a protocol for dimerization 
of the quinazolinone monomers using reactions which have the following qualities: no 
protection-deprotection strategies, mild reaction conditions, high yields and easy 
purifications. It was decided to take the click chemistry approach considering high yields, 
mild conditions and easy purification are one of the main characteristics of this reaction. 
Another advantage of this reaction is that there is no stereochemical complication. Using 
copper sulfate (CuSO4) as a catalyst at room temperature affords exclusively the 1,4-
regioisomer.
71
 This 1,4-regioisomer was confirmed using NMR spectroscopy as 
mentioned in the experimental section. After careful optimization and manipulation of the 
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solvent systems and catalyst, the reaction was calibrated to afford maximum yields.  
Thus, it was now possible to dimerize molecules with free hydroxyl groups. Monomers 
having a variety of functional groups, i.e. hydroxyl, acetyl and methoxy were tested to 
ensure the compatibility of this reaction with these functional groups. Monomers with up 
to two hydroxyl groups were successfully dimerized to the product having four free 
hydroxyl groups. This was achieved at yields ranging from 60-80 %. Unlike Suzuki 
reaction, where the coupling reaction is very efficient but preparation of the desired 
monomers is difficult, in this case preparation of the monomers for the click reaction was 
relatively easy consisting of SN2 reactions at room temperature, quantitative yields and 
easy purification. Since, this protocol is now well established, efforts are on in our lab to 
increase the number and diversity of these hydroxyl groups with the aim of having dimers 
with greater structural diversity. 
3.2 Non-aqueous purification of sulfated molecules 
As mentioned previous, the major hurdle in synthesizing a library of small 
sulfated molecules was the considerable loss of yield and time due to the aqueous 
purification process like size exclusion chromatography. Because of extremely dilute 
chromatographic fractions, to overcome the limit of detection, the sample size for 
purification had to be in excess of 200 mg. This might not seem like a lot but if the 
synthetic scheme involves a large number of steps before sulfation, most often than not 
the first step has to be performed in multi-gram quantities to end up with the required 
amount. This results in rise in expense, not only due to the high amounts of starting 
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material used, but also in terms of the solvents and keeping the cost per reaction low is a 
very important parameter for the synthesis of such a library. For size exclusion 
chromatography to be performed, the column needs to be washed with the 
chromatographic vehicle, that is water for 12 hours. This is then followed by loading the 
sample and eluting it for the next 12 hours. The fractions containing the compound of 
interested are pooled together and lyophilized, which takes approximately 24 hours 
before it can be subjected to cation exchange. Thus, the total time required for such 
purifications is in excess of 48 hours. We had hypothesized earlier that considering the 
highly lipophilic backbone, if the charge of the sulfate is masked in some way, it would 
allow non-aqueous means to be employed for purification. The sulfation reaction was 
carried out in sulfur trioxide complexed with triethyl amine. The triethyl amine counter 
ion is sufficiently lipophilic to mask the charge of the sulfate. As expected, when 
subjected to normal phase silica gel column chromatography, using dichloromethane and 
methanol (0-20 %) as the solvent system, the dimers with as many as four sulfate groups 
could be easily chromatographed. With the success of this technique, such purifications 
were tried using a flash chromatography using the same solvent system, aiming to further 
reduce the purification time and further reducing the minimum sample size required for 
purification. This method was extremely successful and dimers with as many as four 
sulfate groups could be easily purified. The phenomenally low purification time (15 
minutes) and low sample size requirements (15 mg) has made this a very valuable 
development towards the synthesis of libraries of small sulfated molecules.  
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Table 6 The following table gives a comparison between the different aspects of 
aqueous and non-aqueous chromatography. 
Parameters Aqueous  Non-aqueous 
Eluent Water DCM : MeOH (0-20 %) 
Separation media Sephadex G-10 Silica gel 
Time ~ 48 hrs. ~ 0.25 hrs. 
Minimum sample size 200 mg 15 mg 
 
3.3  Screening against coagulation enzymes 
The synthesized compounds were screened against factor Xa, thrombin and factor 
XIa, the most important targets for anticoagulant agents. The synthesized molecules were 
first screened against each enzyme at 500 μM concentration and the residual enzyme 
activity calculated. If any compound showed 0 % residual enzyme activity, i.e. it 
completely inhibits the enzyme at this concentration, then its IC50 was calculated. 
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Figure 124 Factor Xa inhibition. Compounds present at 500 μM. Standard error in 
this experiment was less than 10 %. 
 
Thus, the residual enzyme activity for each compound was greater than 50 % 
indicating that these molecules do not have much inhibitory effects on factor Xa. 
 
 
 
Non-sulfated   
dimer  
Sulfated   dimer  Sulfated   
monomer  
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Firgure 125 Thrombin inhibition. Compounds present at 500 μM. Standard error in 
this experiment was less than 10 %. 
In case of thrombin, the non-sulfated dimers were found to be inactive with the 
residual enzyme active for each compound not going below 50 %. The same was 
observed for the sulfated monomers. However, in case of the sulfated dimers, a clear 
trend is evident. „CS2‟ has one sulfate group, „CS3‟ has two sulfates, „CS4‟ and „CS9‟ 
also have two sulfates but with additional acetyl and methoxy groups respectively. „CS5‟, 
„CS7‟ have three sulfates and „CS8‟ has four sulfate groups (Figure 3). Thus, as the 
number of sulfate group increases from 1-4 the inhibitory activity with respect to 
thrombin decreases. 
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Figure 126 Structures of the sulfated dimers CS2, CS3, CS4, CS5, CS7, CS8, CS9. 
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Figure 127 Factor XIa inhibition. Compounds present at 500 μM. Standard error in 
this experiment was less than 10 %. 
 
For factor XIa, yet again the non-sulfated dimers did not show any substantial 
inhibition. However, for sulfated dimers, again there is an interesting trend which is 
present. The mono-sulfated molecule „CS2‟ was completely inactive. The compounds 
containing 2 and 3 sulfates viz. CS3, CS4, CS5, CS7 and CS9 almost completely 
inhibited the enzyme at 500 μM. While „CS8‟ which has 4 sulfates was again inactive. In 
order to make a better comparison between CS3, CS4, CS5, CS7 and CS9 their IC50‟s 
were determined. 
Non-sulfated   
dimer  
Sulfated   dimer  Sulfated   
monomer  
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Figure 128 IC50 curve for CS3 
 
 
 
 
 
 Coefficient Std. Error t P 
logIC50 -2.0817 0.0052 -403.315 <0.0001 
Ym 98.1641 0.3262 300.9777 <0.0001 
Yo 1.81E-09 0.2564 7.07E-09 1 
HS 3.9574 0.1881 21.0357 <0.0001 
Figure 129 IC50 curve for CS4 
 
 
 
 
 
 Coefficient Std. Error t P 
logIC50 -0.8159 0.007 -116.8752 <0.0001 
Ym 96.2958 0.6338 151.9312 <0.0001 
Yo 5.58E-09 0.5984 9.33E-09 1 
HS 5.3502 0.3011 17.7659 <0.0001 
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Figure 130 IC50 curve for CS9 
 
 
 
 
 
 Coefficient Std. Error t P 
logIC50 -0.8579 0.008 -106.6184 <0.0001 
Ym 95.1395 0.783 121.5022 <0.0001 
Yo 4.18E-01 0.6098 6.86E-01 0.5185 
HS 5.85 0.31 18.8724 <0.0001 
Figure 131 IC50 curve for CS5 
 
 
 
 
 
 Coefficient Std. Error t P 
logIC50 -0.6719 0.0114 -59.0696 <0.0001 
Ym 92.6748 1.4844 62.4327 <0.0001 
Yo 5.30E-02 1.9056 2.78E-02 0.9785 
HS 4.8683 0.6124 7.9492 <0.0001 
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Figure 132 IC50 curve for CS7 
 
 
 
 
 
 Coefficient Std. Error t P 
logIC50 -0.5646 0.0094 -60.0924 <0.0001 
Ym 90.5654 1.0855 83.4344 <0.0001 
Yo 3.11E-10 0.9839 3.16E-10 1 
HS 4.0509 0.3327 12.1744 <0.0001 
Thus, summarizing the above results, the simplest structure CS3 having just two 
sulfates is the most potent with an IC50 of 4.86 μM. As the substitutions increase, as in 
the case of CS4 and CS9 the IC50 goes up to 152.79 and 138.70 μM respectively. Both 
CS5 and CS7 have 3 sulfates and their IC50‟s are 212.86 and 272.52 respectively. Hence, 
as the number of sulfates increases from 2 to 3 the potency decreases. 
Even more interesting is the level of specificity of these interactions. From the 
above results, it is evident that by changing the number of sulfates present in the 
molecule, there are subtle changes in the specificity for different enzymes. While the 
monosulfated CS2 is the most potent compound in case of thrombin, it is completely 
inactive in case of factor XIa and factor Xa. Similarly, CS3 which has an IC50 of 4.86 
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μM for factor XIa, is inactive for factor Xa and weakly interacts with thrombin (residual 
enzyme activity 22 % at 500 μM). Figure 10 provides a comparison of this sulfate 
mediate selectivity for different enzymes. 
Figure 133 Residual enzyme activity comparison between factor Xa, thrombin 
and factor XIa for sulfated dimers CS2, CS3, CS4, CS9, CS5, CS7, CS8. The x-axis 
depicts the compound number followed by the substitution pattern. 
 
Further, the next graph is a plot of the IC 50 for factor XIa giving a better idea of 
the structural requirements for factor XIa inhibition. 
factor Xa  thrombin  thrombin  
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Figure 134 Plot of IC 50 of sulfated dimers CS2, CS3, CS4, CS9, CS5, CS7, CS8. 
X-axis represents the important functional groups present on each compound. 
 
Thus, as expected, small change in the charge density can lead to a considerable 
change in the activity. The best molecule „CS3‟ is very interesting as it is considerably 
potent towards factor XIa inhibition (IC 50 = 4.86 μM), considerably selective for this 
enzyme and hence, can be used as a lead for developing a better more selective molecule. 
 
 
CS2 CS3 CS4 CS9 CS5 CS7 CS8 
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3.4 Advantages of targeting factor XIa 
The pathway for thrombus formation involves mainly two phases, the initiation 
phase and amplification phase.
6
 Tissue factor (TF) is present on the cell surface and upon 
vascular injury this TF is exposed. This exposed TF, activates factor VII (to VIIa) and 
forms a TF-VIIa complex. This complex, further activates factor IX (to IXa) and factor X 
(to Xa). Factor Xa ultimately activates prothrombin to thrombin. Tissue factor pathway 
inhibitor (TFI) and antithrombin normally inhibit this thrombin generation rapidly. 
However, small amounts of residual thrombin can activate fator XI (to XIa) which 
subsequently activates platelet bound factor IX (to IXa). This is the beginning of the 
amplification phase. The factor XIa then generates thrombin via factor Xa mediated 
activation which results in localized thrombus formation at the sites of injury.
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 Figure 
12 gives a schematic representation of the above mentioned phases. Its well known that 
LMWH, UFH and warfarin, target multiple coagulation factors due to which this therapy 
is associated with bleeding complications and a narrow therapeutic window. Although, 
fairly selectively thrombin and factor Xa inhibitors are available, since these act on the 
initiation phase, they affect the normal hemostasis and thus create opportunities for 
bleeding complications. Also, being fairly new, their clinical efficacy and safety are still 
being studied.
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 Conversely, since factor XIa is a part of the amplification phase, 
targeting factor XIa will reduce thrombus formation and since this will not affect the 
initiation phase, it would not affect the hemostasis and thus, should not present any 
bleeding complications. Further proof of the safety in targeting factor XIa was provided 
by Hanson and Gruber. They  demonstrated using a baboon thrombosis model, that 
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inhibition of factor XIa using a anti factor XIa antibody, did not prevent thrombus 
initiation, yet it reduced the intraluminal thrombus growth to a significant extent. Even 
more significantly, this antibody, did not prolong the bleeding time.
67
 Thus, targeting 
factor XIa seems like a promising strategy in order to develop safe as well as efficacious 
drugs. 
Figure 135 Schematic representation of the initiation and amplification phases in 
the coagulation cascade. (Figure adapted from Gailani, D.; Renne, T. Intrinsic pathway 
of coagulation and  arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2507-
2513.) 
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3.5 Probable binding site 
Factor XIa, a serine protease, exists as a disulfide linked homodimer having a 
molecular mass of approximately 160 kDa. Within each monomer, the N-terminal heavy 
chain contains four „apple domains‟ which are basically repeating loops of 90-91 amino 
acids. Natural ligands such as factor XI and other platelet glycoproteins bind at this site.
68
 
The C-terminal of each monomer contains the catalytic domain.
69
 The binding sites for 
heparin are located in two areas, the apple-3 domain, where the basic residues present 
interact with heparin and the catalytic domain.
70
 Since, CS3 is designed to mimic 
heparin, it is possible that it binds to the apple-3 domain. Another observation that also 
suggests binding of CS3 to apple-3 is the observed selectivity. All serine protease share 
similar homology, especially at the active site. Thus, it is extremely difficult to achieve 
selectivity for an active-site inhibitor. However, there might be considerable difference at 
other sites. Heparin exploits the basic residues at allosteric sites, leading to a 
conformation change, finally causing inhibition. At this point, the data suggests that CS3 
also binds at an allosteric site, which could most probably be the apple-3 domain, 
however this can be readily verified by performing Michaelis-Menten kinetics 
experiment. If this is the case, then it will be significantly easy to maximize the affinity 
while maintaining or even improving the selectivity. 
3.6 Summary 
Thus, it is evident that subtle changes in structure can lead to enormous changes in 
affinity, selectivity etc. towards different proteins. Before beginning this study, the main 
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aim was to establish a protocol for dimerization and non-aqueous purification of sulfated 
molecules with the final aim of making the synthesis of a library of small sulfated 
molecules a possibility. The need was this library was emphasized in the beginning and 
the outcome of testing this small library has supported our claim. However, a larger 
library would provide us with even more information and hopefully, it will one day be 
possible to predict the effect of a sulfated molecule on a protein. Also, from the results of 
the biological screening, the importance of sulfation is clear, with all the unsulfated 
molecules being inactive. Further, the sulfated monomers also were inactive or weakly 
active, indicating the need for making dimers and possibly in the future, trimers and 
tetramers. The aim and focus of our lab has been to understand this complex system, as 
drug discovery and design is only a byproduct of this understanding.
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Chapter 4 Future Directions 
 
‘CS3’ seems like a promising lead, having an IC 50 of 4.86 μM against factor XIa with 
considerable selectivity. However, further studies will enable us to optimize the design 
and attain better activity as well as selectivity. A „two-pronged‟ approach consisting of 
synthetic exploration and biochemical studies might be a good way to further explore this 
lead and optimize its structure. 
4.1 Synthetic exploration 
The structure of CS3 leaves great room for making further modifications with a view of 
achieving maximum inhibitory potential. Since the non-sulfated analogue of CS3 was 
found to be inactive, the importance of the sulfate group for activity is well established. 
However, the position of the sulfate group can be modified further to check for any effect 
on activity (Table 7). The chain length for the azide as well as propargyl linker can also 
undergo substantial exploration to optimize the chain length. The best way to do this 
efficiently would be to reduce one carbon from the azide side first and depending on the 
outcome of this chain length reductions further modifications can be made (Table 8). 
Once the optimum structure is established, the 1,5-regioisomer of that analogue can be 
synthesized to analyze the effect of this subtle change in geometry (Figure 137).  
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Figure 136 Possible structural modifications 
 
  
 
 
 
 
Table 1 Modification of R1 and R2 (Color red represents substitution pattern 
of CS3) 
R1 R2 
3-SO3
-
 3-SO3
-
 
2-SO3
-
 2-SO3
-
 
4-SO3
-
 4-SO3
-
 
2-SO3
-
 H 
3-SO3
-
 H 
4-SO3
-
 H 
H 2-SO3
-
 
H 3-SO3
-
 
H 4-SO3
-
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Table 2 Modifications of n1 and n2 (Color red represents substitution pattern 
of CS3) 
n1 n2 
4 1 
3 1 
2 1 
4 2 
4 2 
3 2 
2 2 
3 3 
 
Figure 137 1,5-regioisomer of the optimized structure 
 
 
 
 
 
 
 
4.2 Biochemical studies and x-ray crystallography 
Since these molecules are synthesized as heparin analogues, it is hypothesized that they 
bind to the heparin binding site on factor XIa. However, this needs to be confirmed by 
doing several biochemical experiments. The simplest experiment which would give us an 
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idea if it is binding to a site other than the active site is the Michaelis-Menten kinetics 
experiment. This experiment will also provide information about the inhibition, whether 
competitive, non-competitive or uncompetitive.  
If the above mentioned experiment indicates allosteric binding, then competitive studies 
with heparin would provide further insight about the binding site of the molecule. 
Further, crystallization of the optimized inhibitor with factor XIa (human or bovine) 
would provide conclusive evidence about the binding site and more important binding 
mode of the molecule. This will also provide the interacting amino acids and thus 
broaden the scope to optimize the interactions and thus attain its maximum inhibitory 
potential. 
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